Design and application of niosomal drug delivery systems by Ag Seleci, Didem
  
 
Design and Application of Niosomal 
Drug Delivery Systems 
 
 
Von der Naturwissenschaftlichen Fakultät der 
Gottfried Wilhelm Leibniz Universität Hannover 
 
 
zur Erlangung des Grades 
Doktorin der Naturwissenschaften (Dr. rer. nat.) 
 
 
genehmigte Dissertation 
von 
Didem Ag Seleci, Master’s Degree (Türkei)  
geboren am 15.01.1987 in Izmir, Türkei 
 
 
2017 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Referent:                   Prof. Dr. Thomas Scheper 
Korreferentin:           Apl. Prof. Dr. med. Cornelia Blume 
Tag der Promotion:   01.12.2017 
  
i 
 
 
 
 
 
Dedication 
 
I dedicate this dissertation to my parents Feride and Ismail, my brother 
Ibrahim and the meaning of my life Muharrem.Without your support, trust 
and love my success would not have been possible. 
 
 
Didem Ag Seleci 
Hannover, 2017  
 
 
 
Acknowledgement 
ii 
 
Acknowledgement 
I would like to express appreciation to my supervisor Prof. Dr. Thomas Scheper for 
giving me the opportunity to conduct my study in his group and for the excellent working 
conditions and his support during my thesis. I also would like to thank my committee 
members, Prof. Dr. Cornelia Blume and Prof. Dr. Juergen Alves their acceptance to 
provide further expertise. 
I would like to express my sincere gratitude to Dr. Frank Stahl for his precious support, 
guidance, and confidence. His encouragement provided me a high motivation during my 
study.  
I would also like to give special thanks to Dr. Johanna-Gabriela Walter for her excellent 
advice and numerous fruitful discussions throughout my work. My deepest thanks go to 
Dr. Rebecca Jonczyk who has always been there for me since my master study. She 
provided me extensive personal and professional guidance and taught me a great deal 
about both scientific research and life in general. I also wish to thank Dr. Antonina 
Lavrentieva for her valuable instructions in cell culture experiments.  
I also would like to thank Martina Weiß for her kind help, support, and patient during 
my HPLC measurements. Martin Pähler, Cornelia Alic, Ulrike Dreschel, Ivo Havlik and 
Michael Dors, thank you all for making everything easily accessible in the institute, 
always friendly answers and IT support.  
I would like to express my thanks to all the members of Institute Technical Chemistry 
but especially to Harshvardhan Modh for having a great time, kindly friendship, and long 
conversations. I also thank Andre Jochums for nice collaborations in flow cytometry 
experiments. My office colleagues Steffi, Tracy and Sebastian, thank you all for very 
effective and friendly atmosphere in the office. Especially, Steffi thank you for a great 
time in English classes. 
I am very grateful to Anna Glyk, Saher Hamid, and Narmina Balayeva who did not let 
me feel alone in my lonely time in Hanover. I also thank Esta & Janis, Nuran & Özgür, 
Zeynep & Hakan, Bahar & Erkan, and Basak & Sertac for spending pleasant time 
together.   
My hearty and deepest thanks go to Dr. Rebecca & Patrick Jonczyk, without your 
priceless friendship it would be everything too difficult by the starting our new life in 
Hanover. They made me feel loved and never feel alone. I feel very lucky to have you 
and I am sure that our friendship will always remain. I want to thank Dr. Mehriban 
Ulusoy who has sharing always her valuable experiences with us and has answered the 
Acknowledgement 
iii 
 
entire questions patiently. Mihri & Mem, thank you for your nice visits and great time 
that we had together.  
I feel very happy to meet with you, Hermann & Sigrid. Sigrid, I appreciate you for our 
meetings with fruitful discussions and your precious advice. Hermann, thank you for 
your amazing knowledge you shared with us and your help by fixing the combi boiler.  
My all supervisors and teachers who contributed substantially efforts in getting my 
doctoral degree, especially, Prof. Dr. Suna Timur, Assoc. Prof. Dr. Dilek Odaci 
Demirkol, Kerstin Reichart de Flores and Nurcan Yildiz, they have supported me all the 
time, always make me feel special and I appreciate them.  
I would also like to thank Konrad Adenauer Foundation for their financial support 
granted through doctoral fellowship and great seminars that provided me excellent 
qualifications and numbers of new friends. Especially, Dr.h.c. Berthold Gees thank you 
for your kind encouragement and supervision since last three years.  
Last but not least, I would like to express my deepest thanks to my mother, father, 
brother, the family of my husband, and my best friends Elcin, Karina, Tayfun, Funda and 
Berat for being patient and their endless support. I feel very lucky to have all you in my 
life. My biggest thanks go to my dear best friend, smart colleague and at the same time 
loving husband Muharrem. Thank you for the every glorious moment and amazing 
stories we had together since last ten years. I love you all.  
 
 
 
 
 
 
Abstract 
iv 
 
Abstract 
Cancer is currently a serious health problem leading cause of death worldwide. The most 
used treatment for cancer is chemotherapy and the therapeutic efficacy of many 
anticancer drugs is limited by their poor penetration into tumor tissue and by their side 
effects on healthy cells. Nanotechnology in cancer diagnosis and therapy provides new 
aspects by developing novel nanomaterials such as nanoparticles that can deliver the 
loaded agents to the tumors without damaging healthy cells.  
Niosomes are non-ionic surfactant vesicles having a bilayer structure with biodegradable 
and nonimmunogenic feature. They can be produced at low costs and exhibit high 
stability making them very attractive drug carriers in drug delivery studies. Especially, 
easy modification of their composition and surface allows development of novel targeted 
drug delivery systems.  
Within the scope of this thesis, the design of different niosomal drug delivery systems 
and their applications in targeted cancer therapy were evaluated. Firstly, polyethylene 
glycolated niosomes were synthesized as a drug carrier and anticancer drug doxorubicin 
was encapsulated into the niosomes. To ensure an effective targeted drug delivery, an 
aptamer specifically binding to cell surface protein MUC1 protein was conjugated to a 
cell penetrating peptide followed by binding to the surface of the niosomes. In a second 
approach, polyethylene glycolated niosomes were used to develop a targeted co-drug 
delivery system against brain cancer. Curcumin and doxorubicin were entrapped into the 
niosomes and the niosomal surface was decorated with a tumor homing and penetrating 
peptide, which penetrates tumor cells via Neuropilin-1 receptor mediated endocytosis.  
In conclusion, in the present work two new different targeted niosomal drug delivery 
systems against ovarian and brain cancer were designed, synthesized, characterized and 
applied in vitro. These studies may provide new insights for the development of effective 
targeted therapy in cancer. 
 
Key words: niosomes, structure and characterization, targeted drug delivery, co-drug 
delivery
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Kurzfassung 
Krebs ist derzeit ein ernstes Gesundheitsproblem und die führende Todesursache 
weltweit. Die am häufigsten verwendete Behandlung von Krebs ist die Chemotherapie. 
Die therapeutische Wirksamkeit vieler Krebsmedikamente ist auf Grund ihrer schlechten 
Durchdringung in das Tumorgewebe und durch ihre Nebenwirkungen auf normale, 
pathologisch unveränderte Zellen begrenzt. Hier bietet die Nanotechnologie neue Asätze 
in der Krebsdiagnose und -therapie, indem neuartige Nanomaterialien wie z.B. 
Nanopartikel entwickelt und eingesetzt werden. Sie können mit Arzneimittel beladen 
werden und diese direkt den Tumorzellen zuführen, ohne die gesunden Zellen zu 
beschädigen. Niosome sind nichtionische Tensid-Vesikel mit einer 
Doppelschichtstruktur, die biologisch abbaubar und nicht-immunogen sind und mit 
niedrigen Kosten sowie in hoher Stabilität hergestellt werden können. Das macht sie zu 
sehr attraktiven Arzneimittelträgern in drug delivery-Studien. Eine einfach darstellbare 
Modifikation ihrer Zusammensetzung und Oberfläche ermöglicht die Entwicklung 
neuartiger, individualisierter und zielgerichteter drug delivery-Systeme, die sowohl 
Patienten- als auch krankheitsspezifisch desingt werden können. 
Im Rahmen dieser Arbeit wurde unterschiedliche niosomale Arzneimittelabgabesysteme 
erstmalig selbst hergestellt, modifiziert, Oberflächen-dekoriert, physiko-chemisch 
charakterisiert und deren Design und Anwendungen im gezielten in-vitro Biotesting 
evaluiert. Polyethylenglykol-Niosome wurden als Arzneimittelträger synthetisiert, in die 
das Antikrebsmedikament Doxorubicin eingekapselt war. Um eine zielgerichtete 
Arzneimittelabgabe gegen Eierstocktumore zu gewährleisten, wurde ein an das 
Zelloberflächenprotein MUC1 spezifisch bindendes Aptamer über einen Peptidlinker, 
der die Zellpenetration ernöglicht, an die Oberfläche der Niosomen gebunden. In einem 
zweiten Ansatz wurden Polyethylenglykol-Niosome verwendet, um ein Ko-
Arzneimittelabgabesystem zielgerichtet gegen Hirntumore zu entwickeln. Die beiden 
Wirkstoffe Curcumin und Doxorubicin wurden in die Niosome eingeschlossen und an 
die Niosomoberfläche wurde ein Tumor-Homing und tumordurchdringendes Peptid 
gebunden, das über eine Neuropilin-1-Rezeptor vermittelte Endozytose in die 
Tumorzellen eindringt.  
In der vorliegenden Arbeit wurden somit in vitro zwei neue, hochspezifische niosomale 
Arzneimittelabgabesysteme gegen Eierstock- und Hirntumor selbst entwickelt, 
charakterisiert und angewendet. Diese Studien können neue Erkenntnisse zur 
zukünftigen Entwicklung effektiver, gezielter Krebstherapien liefern. 
Stichwörter: Niosomen, Struktur und Charakterizierung, zielgerichtete 
Arzneimittelabgabe, Ko-Arzneimittelabgabesystem 
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1. Introduction 
One of the most active research areas of nanotechnology is nanomedicine, that applies 
the knowledge and tools of nanotechnology to the prevention, diagnosis, and treatment 
of the diseases. Drug delivery systems (DDS) are defined as formulations or devices 
enabling the transportation of a drug in the desired part of the body. By using nanoscale 
delivery vehicles, multiple tasks could be performed simultaneously, such as the 
controlling the delivery of the therapeutic agents to the target side and enhancing 
bioavailability of poorly soluble drugs. Therefore, the efficiency of the agents can be 
improved.  
Multifunctional nanoparticles, acting as a drug vehicle, can be precisely fabricated with 
appropriate physicochemical properties. Their size, shape, composition and physical 
parameters can be finely tuned. Nanoparticles can be constructed from various organic 
and inorganic materials resulting in liposomes, niosomes, carbon nanotubes, quantum 
dots, micelles, metal nanoparticles, or dendrimers. By coating of their surface with 
hydrophilic polymers, their circulation time in the body could be enhanced through 
decrease of enzymatic degradation. Polyethylene glycol (PEG) is one of the most used 
non-toxic, non-immunogenic, non-antigenic, and highly water-soluble coating polymer 
for drug delivery studies. Due to these favorable properties, PEGylation plays an 
important role in the development of novel drug delivery devices.  
In the treatment of cancer, delivery systems attempt to improve the therapeutic index of 
anticancer agents by efficiently directing them to tumor cells. This can be achieved by 
active targeting. Receptors overexpressed or specifically expressed by cancer cells are 
unique targets. The surface of the nanoparticles may be functionalized by using 
biomolecules such as antibodies, aptamers, peptides and small molecules that bind 
specifically to these receptors. Thus, high specificity and penetration capabilities that are 
crucial for cancer treatment can be gained. Aptamers are single stranded oligonucleotides 
and one of the most promising targeting ligands that bind specifically to cancer cell 
surface receptors with high affinity. This property of aptamers has been utilized for 
developing targeted drug carriers which can deliver several types of cargos into the cells. 
On the other hand, cell penetrating peptides (CPPs) have been widely employed as 
delivery vectors for the import of the molecules that otherwise cannot cross the plasma 
membrane of eukaryotic cells. The combination of targeting ligands and penetration 
enhancing peptides could open new perspectives.  
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In the recent years, niosomes have gained great attention in drug delivery studies. 
Niosomes are vesicular systems which are mostly formed by non-ionic surfactants and 
cholesterol. They exhibit low toxicity and high biocompatibility with the biological 
systems. Besides, their simple preparation, low cost, and high stability make them 
outstanding candidates for drug delivery. Because of their hydrophobic bilayer and 
hydrophilic core, niosomes can load both hydrophobic and hydrophilic therapeutic 
agents. Furthermore, with the PEGylation of niosomes their surfaces are functionalized 
easily for biomolecule conjugation. Hereby, stability, bioavailability, as well as 
therapeutic efficiency of the encapsulated agent are improved by using a protecting and 
targeting vehicle. Especially for the treatment of cancer, the prolonged and specific 
delivery of chemotherapeutic agents plays a key role to reduce side effects and increase 
the therapeutic efficacy. In this context, PEGylated niosomes facilitate the design of 
various targeted niosomal drug delivery systems bearing great potential for 
commercialization.  
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2. Aim and Scope 
Development of multifunctional nanoparticles offers great hope to overcome some 
challenges faced in diagnosis, therapy, and monitoring of many types of cancer. 
Nanoparticles provide an opportunity to reduce toxicity and enhance therapeutic 
efficiency. Vesicular nanoparticles such as niosomes are the leading structures that are 
used in drug delivery applications. In this thesis design, development, and application of 
novel niosomal drug delivery systems for targeted cancer therapy were aimed. In the 
theoretical part, the structure and preparation methods of niosomes are summarized by 
considering characterization techniques. The recent studies on niosomal drug delivery 
systems are discussed with special focus on brain targeting. Then the design and 
production of targeted niosomal drug carriers are presented in the experimental section.  
In the first experimental part, the development of an effective carrier with targeting 
moiety to overcome penetration problem in solid tumors was aimed. For this aim, 
PEGylated niosomes were synthesized to obtain nanostructures. To test the applicability 
of cell penetrating peptide and aptamer, the surface of niosomes were modified with 
CysTAT peptide and MUC1 aptamer binding to MUC1 protein found on the cell 
membrane. Doxorubicin (DOX) as a cancer model drug was encapsulated into the 
platform and niosomes were characterized in detail. In vitro studies were carried out on 
MUC1 positive HeLa and negative U87 cells to investigate the specificity of the designed 
niosomal system as well as the influence of drug-loaded niosomes on the viability of 
selected cancer cells. 
In the second part of experimental section, a novel drug delivery system was developed 
against brain tumors. The therapeutic efficacy of many anticancer drugs is limited 
because of the blood-brain barrier (BBB). Therefore, development of novel therapy 
methods is quite important. Targeted co-drug delivery could be a promised strategy as 
was shown in recent studies. The objective of this study was to create a novel niosomal 
co-drug delivery system targeted to glioblastom. Accordingly, doxorubicin and curcumin 
were loaded into PEGylated niosome and the surface of niosome was modified with 
tumor homing and penetrating peptide (tLyp-1). The characterization studies were 
performed for niosomal formulations. In vitro studies were carried out by using 
glioblastoma (U87) and human mesenchymal stem cells (hMSC) cells to investigate the 
specificity and cytotoxicity of the tLyp-1 targeted co-drug loaded niosomal formulation.  
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3. Theoretical Background 
This chapter is divided into two subchapters. Chapter 3.1 (review article) provides 
fundamental information about niosomes including the structure, synthesis and 
applications in drug delivery. Chapter 3.2 (book chapter) focuses on the targeting 
strategies and potential of niosomes for brain targeting. 
 
3.1 Review Article - Niosomes as nanoparticular drug carriers: 
Fundamentals and recent applications 
This chapter comprises the review article ‘Niosomes as Nanoparticular Drug Carriers: 
Fundamentals and Recent Applications’ by D. Ag Seleci, M. Seleci, A. Jochums, J.G. 
Walter, F. Stahl and T. Scheper, Journal of Nanomaterials, Article ID 7372306. It was 
reprinted by permission of Hindawi Publishing Corporation.  
 
3.1.1 Summary 
Drug delivery is a process of administration of pharmacological molecules to create a 
therapeutic effect, preferably in the diseased area. However, conventional drug delivery 
systems suffer from limitations such as lack of specificity, poor solubility, and overdose 
toxicity. Nanoparticles as drug carriers have aroused a great interest in drug delivery 
studies because of their multifunctional character. This character enabled delivery of 
therapeutic load with a controlled rate and high specificity. Niosomes are one of the most 
promising vesicular drug delivery systems that have a bilayer structure composed of non-
ionic surfactants and cholesterol.  
In the first part of this review article, material composition of niosomes, their effects on 
vesicle structure and stability are summarized. Varieties of techniques are used to 
synthesize niosomes. All these methods are explained in detail. The physicochemical 
properties of niosomes such as size, morphology, zeta potential, and stability as well as 
their characterization techniques are described. The effects of niosomes’ 
physicochemical properties in biological applications are also evaluated. Furthermore, 
the applications of niosomes as drug carrier for various types of chemotherapeutic agents 
are described via review of recent studies. The combination of ligand-mediated active 
targeting strategies with niosomal drug delivery systems is listed in this present review. 
Besides, the importance of co-drug delivery systems for the development of effective 
cancer therapy and the application potential of niosomes as a co-drug carrier are 
discussed.  
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Finally, recent applications of niosomes in drug delivery are summarized.        
  
3.1.2 Abstract 
Drug delivery systems are defined as formulations aiming for transportation of a drug to 
the desired area of action within the body. The basic component of drug delivery systems 
is an appropriate carrier that protects the drug from rapid degradation or clearance and 
thereby enhances drug concentration in target tissues. Based on their biodegradable, 
biocompatible, and nonimmunogenic structure, niosomes are promising drug carriers 
that are formed by self-association of nonionic surfactants and cholesterol in an aqueous 
phase. In recent years, numerous research articles have been published in scientific 
journals reporting the potential of niosomes to serve as a carrier for the delivery of 
different types of drugs. The present review describes preparation methods, 
characterization techniques, and recent studies on niosomal drug delivery systems and 
also gives up to date information regarding recent applications of niosomes in drug 
delivery.  
 
3.1.3 Introduction 
Delivering drug with a controlled rate and targeted delivery received much attention in 
recent years. The application of nanotechnology to medicine has provided the 
development of multifunctional nanoparticles that, acting as drug carriers, can be loaded 
with different drugs. Nanocarriers present a great approach in drug delivery with 
promising features such as protection of drug from degradation and cleavage, controlled 
release, and in case of targeted delivery approaches the delivery of drug molecules to the 
target sites [1]. Niosomes are one of the promising drug carriers that have a bilayer 
structure and are formed by self-association of nonionic surfactants and cholesterol in an 
aqueous phase. Niosomes are biodegradable, biocompatible, and nonimmunogenic. They 
have long shelf life, exhibit high stability, and enable the delivery of drug at target site 
in a controlled and/or sustained manner [2]. In recent years, the potential of niosomes as 
a drug carrier has been extensively studied [3–5]. Various types of nonionic surfactants 
have been reported to form niosomes and enable the entrapment of a large number of 
drugs with a wide range of solubility [6–8]. The composition, size, number of lamellae, 
and surface charge of niosomes can be varied and optimized to enhance the performance 
of niosomes for drug delivery. The aim of this review is to present the fundamentals of 
niosome preparation and characterization as well as a description of their use in drug 
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delivery, with particular attention to more recent studies. This review will provide an 
overview on the increasing interest on niosomes in the field of drug delivery. 
 
3.1.4 Structure and components of niosomes 
The main components of niosomes are nonionic surfactants, hydration medium and lipids 
such as cholesterol. The list of materials used in the preparation of niosomes has been 
shown in Table 3.1. The self-assembly of nonionic surfactants in aqueous media results 
in closed bilayer structures (Figure 3.1). A high interfacial tension between water and the 
hydrophobic tails of the amphiphile causes them to associate. The steric and hydrophilic 
repulsion between the head groups of nonionic surfactant ensure that hydrophilic termini 
point outwards and are in contact with water. The assembly into closed bilayers usually 
requires some input of energy such as mechanical or heat. Niosomes can be categorized 
in three groups according to their sizes and bilayers. Small unilamellar vesicles (SUV) 
(10–100 nm), large unilamellar vesicles (LUV) (100–3000 nm), and multilamellar 
vesicles (MLV) where more than one bilayer is present. 
 
Table 3.1 The materials used in niosome preparation 
Non-ionic surfactants Examples References 
Alkyl ethers   
 Alkyl glycerol ethers Hexadecyl diglycerol ether (C16G2) [9] 
 Polyoxyethylene glycol 
alkyl ethers (Brij) 
Brij 30, Brij 52, Brij 72, Brij 76, Brij 78 [10-12] 
Crown ethers Bola [13,14] 
Alkyl esters   
 Sorbitan fatty acid esters 
(Spans) 
Span 20, Span 40, Span 60, Span 80, Span 65, Span 85 [15-18] 
 Polyoxyethylene sorbitan 
fatty acid esters (Tweens) 
Tween 20, Tween 40, Tween 60,  Tween 80, Tween 65, 
Tween 85 
[7,19,20] 
Alkyl amides   
 Glycosides C-glycoside derivative surfactant (BRM-BG) [21] 
 Alkyl polyglucosides Octyl-decyl polyglucoside (OrCG110), Decyl 
polyglucoside (OrNS10) 
[22] 
Fatty alcohols or fatty acids   
 Fatty alcohols Stearyl alcohol, Cetyl alcohol, Myristyl alcohol [23] 
 Fatty acids Stearic acid, Palmitic acid,  Myristic acid [23] 
Block copolymer    
 Pluronic Pluronic L64, Pluronic 105 [24,25] 
Lipidic components   
Cholesterol  [26] 
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l-α-Soya phosphatidyl choline  [27] 
Charged molecule   
Negative charge Diacetyl phosphate, Phosphotidic acid, Lipoamine acid, 
Dihexadecyl phosphate 
[28,29] 
Positive Charge Stearylamine, Steary piridinium chloride, Cetyl 
pyridinium chloride 
[29] 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Structure of niosomes. 
 
Nonionic surfactants 
Nonionic surfactants are a class of surfactants, which have no charged groups in their 
hydrophilic heads. They are more stable and biocompatible and less toxic compared to 
their anionic, amphoteric, or cationic counterparts [41]. Therefore, they are preferred for 
formation of stable niosome for in vitro and in vivo applications. Nonionic surfactants 
are amphiphilic molecules that comprise two different regions: one of them is hydrophilic 
(water-soluble) and the other one is hydrophobic (organic soluble). Alkyl ethers, alkyl 
esters, alkyl amides, fatty acids are the main nonionic surfactant classes used for niosome 
production. The hydrophilic-lipophilic balance (HLB) and critical packing parameter 
(CPP) values play a critical role in the selection of surfactant molecules for niosome 
preparation. 
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Hydrophilic-lipophilic balance (HLB) 
HLB is a dimensionless parameter, which is the indication of the solubility of the 
surfactant molecule. The HLB value describes the balance between the hydrophilic 
portion to the lipophilic portion of the nonionic surfactant. The HLB range is from 0 to 
20 for nonionic surfactants. The lower HLB refers to more lipophilic surfactant and the 
higher HLB to more hydrophilic surfactant. Surfactants with a HLB between 4 and 8 can 
be used for preparation of vesicle [42]. Hydrophilic surfactants with a HLB value ranging 
from 14 to 17 are not suitable to form a bilayer membrane due to their high aqueous 
solubility [43]. However, with the addition of an optimum level of cholesterol, niosomes 
are indeed formed from polysorbate 80 (HLB value = 15) and Tween 20 (HLB value = 
16.7) [44, 45]. Tween 20 forms stable niosome in the presence of equimolar cholesterol 
concentration. The interaction occurs between the hydrophobic part of the amphiphile 
next to head group and the 3-OH group of cholesterol at an equimolar ratio and this 
interaction could explain the effect of cholesterol on the formation and hydration 
behavior of Tween 20 niosomal membranes [46, 47]. 
Drug entrapment efficiency of the niosomes is also affected by HLB value of surfactant 
[48]. Shahiwala et al. have incorporated nimesulide into niosomes using lipid film 
hydration technique by changing the HLB. They found that as the HLB value of 
surfactant decreases from 8.6 to 1.7, entrapment efficiency decreases [43, 49]. 
 
Critical packing parameter (CPP) 
During the niosomal preparation, the geometry of the vesicle depends upon the critical 
packing parameter. On the basis of the CPP of a surfactant, the shape of nanostructures 
formed by self-assembly of amphiphilic molecules can be predicted. Critical packing 
parameter depends on the symmetry of the surfactant and can be defined using following 
equation [50, 51]: 
CPP= 𝑣Ic×a˳ 
where V is hydrophobic group volume, 𝑙 𝑐 is the critical hydrophobic group length, and 𝑎0 is the area of hydrophilic head group. If CPP ≤ 1/3 corresponding, for example, to a 
bulky head group, small hydrophobic tail spherical micelles may form. Nonspherical 
micelles may form if 1/3 ≤ CPP ≤1/2, and bilayer vesicles can occur if 1/2 ≤ CPP ≤ 1. 
Inverted micelles form if CPP ≥ 1 when the surfactant is composed of a voluminous tail 
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and a small hydrophobic tail [47]. CPP could be considered as a tool for realizing, 
rationalizing, and predicting the self-assembled structure and its morphological transition 
in amphiphilic solutions [52]. 
 
Cholesterol 
In the bilayer structure of niosomes, cholesterol forms hydrogen bonds with hydrophilic 
head of a surfactant [19, 53]. Cholesterol content of niosomes thereby influences the 
structures of niosomes and physical properties such as entrapment efficiency, long time 
stability, release of payload, and biostability [17, 46]. Cholesterol improves the rigidity 
of vesicles and stabilizes niosomes towards destabilizing effects induced by plasma and 
serum components and decreases the permeability of vesicles for entrapped molecules 
thus inhibiting leakage [54]. Drug entrapment efficiency plays an important role in 
niosomal formulations and it can be altered by varying the content of cholesterol. 
Agarwal et al. demonstrated that cholesterol improves the stability of enoxacin loaded 
niosome with increasing cholesterol content, resulting in increases of entrapment 
efficiency [55]. The effect of cholesterol on flurbiprofen entrapment was studied by 
Mokhtar et al. and cholesterol was found to have little effect on the flurbiprofen 
entrapment into Span 20 and Span 80 niosomes. However, a significant increase in 
entrapment efficiency of flurbiprofen was obtained when 10% of cholesterol was 
incorporated into niosomes prepared from Span 40 and Span 60 followed by a decrease 
in encapsulation efficiency of the drug upon further increase in cholesterol content [56]. 
According to the reported results, the addition of cholesterol and its amounts needs to be 
optimized depending on the physical-chemical characteristic of surfactants and loaded 
drugs. 
 
Charged molecule 
Charged molecules increase the stability of the vesicles by the addition of charged groups 
to the bilayer of vesicles. They increase surface charge density and thereby prevent 
vesicles aggregation. Dicetyl phosphate and phosphatidic acid are most used negatively 
charged molecules for niosome preparation and, similarly, stearyl amine and stearyl 
pyridinium chloride are well-known positively charged molecules used in niosomal 
preparations. Normally, the charged molecule is added in niosomal formulation in an 
amount of 2.5–5 mol %. However increasing the amount of charged molecules can 
inhibit niosome formation [29]. 
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 3.1.5 Methods of preparation 
 
Thin-film hydration method (TFH) 
Thin-film hydration method is a simple and well-known preparation method. In this 
method, the surfactants, cholesterol, and some additives such as charged molecules are 
dissolved in an organic solvent in a round bottomed flask. Then the organic solvent is 
removed using a rotary vacuum evaporator to obtain thin film on the inside wall of the 
flask. An aqueous solution of drug is added and the dry film is hydrated above the 
transition temperature (𝑇𝑐) of the surfactant for specified time with constant shaking [57, 
58]. Multilamellar niosomes are formed by this method. 
 
Ether injection method (EIM) 
In ether injection method, the surfactants with additives are dissolved in diethyl ether and 
injected slowly through a needle in an aqueous drug solution maintained at a constant 
temperature, which is above the boiling point of the organic solvent. The organic solvent 
is evaporated using a rotary evaporator. During the vaporization, the formation of single 
layered vesicles occurs [59–61]. 
 
Reverse phase evaporation method (REV) 
 In this method, niosomal ingredients are dissolved in a mixture of ether and chloroform 
and added to aqueous phase containing the drug. The resulting mixture is sonicated in 
order to form an emulsion and the organic phase is evaporated. Large unilamellar vesicles 
are formed during the evaporation of the organic solvent [62–64]. 
 
Microfluidization method  
The microfluidization method is based on submerged jet principle. In this method, the 
drug and the surfactant fluidized streams interact at ultra high velocities, in precisely 
defined micro channels within the interaction chamber. The high-speed impingement and 
the energy involved leads to formation of niosomes. This method offers greater 
uniformity, smaller size, unilamellar vesicles, and high reproducibility in the formulation 
of niosomes [65, 66]. 
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Supercritical carbon dioxide fluid (scCO2) 
Manosroi et al. have described the supercritical reverse phase evaporation technique for 
niosome formation [67, 68].They added Tween 61, cholesterol, glucose, PBS, and 
ethanol into the view cell and the CO2 gas was introduced into the view cell. After 
magnetic stirring until equilibrium, the pressure was released and niosomal dispersions 
were obtained [67]. This method enables one step production and easy scale-up. 
 
Proniosome 
Proniosome technique includes the coating of a water-soluble carrier such as sorbitol and 
mannitol with surfactant. The coating process results in the formation of a dry 
formulation. This preparation is termed “Proniosomes” which requires to be hydrated 
before being used. The niosomes are formed by the addition of the aqueous phase. This 
method helps in reducing physical stability problems such as the aggregation, leaking, 
and fusion problem and provides convenience in dosing, distribution, transportation, and 
storage showing improved results compared to conventional niosomes [69]. 
 
Transmembrane pH gradient 
In this method, surfactant and cholesterol are dissolved in chloroform and evaporated to 
form a thin lipid film on the wall of a round bottomed flask. The film is hydrated with a 
solution of citric acid (pH = 4) by vortex mixing and the resulting product is freeze-
thawed for niosome formation. The aqueous solution of drug is added to this niosomal 
suspension after that phosphate buffer is added to maintain pH between 7.0 and 7.2 [70]. 
According to this method, the interior of niosome has a more acidic pH value than the 
outer medium. The added unionized drug passes through the niosome membrane and 
enters into the niosome. The drug ionizes in an acidic medium and cannot escape from 
the niosomal bilayer [71]. 
 
Heating method 
This is a patented method, which was created by Mozafari et al. [72, 73]. Surfactants and 
cholesterol are separately hydrated in buffer and the solution is heated to 120°C with 
stirring to dissolve cholesterol. The temperature is reduced and surfactants and other 
additives are then added to the buffer in which cholesterol is dissolved while stirring 
continues. Niosomes form at this stage, are left at room temperature, and then are kept at 
4-5°C under nitrogen atmosphere until use [53]. 
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The “bubble” method 
In this method, surfactants, additives, and the buffer are added into a glass flask with 
three necks. Niosome components are dispersed at 70°C and the dispersion is mixed with 
homogenizer. After that, immediately the flask is placed in a water bath followed by the 
bubbling of nitrogen gas at 70°C. Nitrogen gas is passed through a sample of 
homogenized surfactants resulting in formation of large unilamellar vesicles [74]. 
 
3.1.6 Characterization of niosomes 
The characterization of niosome is essential for the clinical applications. Characterization 
parameters have a direct impact on the stability of niosomes and a significant effect on 
their in vivo performance. Therefore, these parameters such as morphology, size, 
polydispersity index (PI), number of lamellae, zeta potential, encapsulation efficiency, 
and stability must be evaluated. 
 
Size and morphology 
Dynamic light scattering (DLS) [75], scanning electron microscopy (SEM) [76], 
transmission electron microscopy (TEM) [77], freeze fracture replication electron 
microscopy (FF-TEM) [68], and cryo-transmission electron microscopy (cryo-TEM) 
[67] are the most used methods for the determination of niosome sizes and morphology. 
DLS provides simultaneously cumulative information of particle size and valuable 
information on the homogeneity of the solution. A single sharp peak in the DLS profile 
implies existence of a single population of scatterers. The PI is helpful in this respect. It 
less than 0.3 corresponds to a homogeneous population for colloidal systems [75]. The 
microscopic approaches are generally used to characterize the morphology of the 
niosomes. 
 
Zeta potential  
Surface zeta potential of niosomes can be determined using zetasizer and DLS 
instruments. The surface charge of niosome plays an important role in the behavior of 
niosomes. In general, charged niosomes are more stable against aggregation than 
uncharged vesicles. Bayindir and Yuksel prepared paclitaxel loaded niosomes and 
investigated the physicochemical properties such as zeta potential of niosomes. They 
found that negative zeta potential values ranging between −41.7 and −58.4mV are 
sufficiently high for electrostatic stabilization of niosomes [12]. 
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Bilayer characterization 
Bilayer characteristics of niosomes have an importance on drug entrapment efficiency. 
The number of lamellae can be determined by AFM, NMR, and small angle X-ray 
scattering (SAXS) for multilamellar vesicles [54]. Membrane rigidity of niosomal 
formulations can be measured by means of the mobility of fluorescence probe as a 
function of temperature [20]. DPH (1,6 diphenyl-1,3,5-hexatriene) is most used 
fluorescent probe and added to niosomal dispersion. DPH normally exists in hydrophobic 
region in the bilayer membrane. The microviscosity of niosomal membrane is determined 
by fluorescence polarization. High fluorescence polarization means high micro viscosity 
of the membrane [78]. Moreover, the bilayer thickness can be characterized using the 
latter method, together with the in situ energy-dispersive X-ray diffraction (EDXD) [79]. 
 
Entrapment efficiency 
Entrapment efficiency (EE%) is defined as the portion of the applied drug which is 
entrapped by the niosomes. Unencapsulated free drug can be removed from the niosomal 
solution using centrifugation [80], dialysis [24], or gel chromatography [81]. After this 
step, the loaded drug can be released from niosomes by destruction of vesicles. Niosomes 
can be destroyed with the addition of 0.1% Triton X-100 or methanol to niosomal 
suspension. The loaded and free drug concentration can be determined by a 
spectrophotometer [82] or high-performance liquid chromatography (HPLC) [83].  
 
Stability 
The stability of niosomes can be evaluated by determining mean vesicle size, size 
distribution, and entrapment efficiency over several month storage periods at different 
temperatures. During storage the niosomes are sampled at regular intervals of time and 
the percentage of drug, which is retained into the niosomes, is analyzed by UV 
spectroscopy or HPLC methods [82, 84]. 
 
 In vitro release 
One often applied method to study in vitro release is based on using of dialysis tubing. 
A dialysis bag is washed and soaked in distilled water. After 30 mins, the drug loaded 
niosomal suspension is transferred, into this bag. The bag containing the vesicles is 
immersed in buffer solution with constant shaking at 25∘C or 37∘C. At specific time 
intervals, samples were removed from the outer buffer (release medium) and replaced 
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with the same volume of fresh buffer. The samples are analyzed for the drug content by 
an appropriate assay method [17]. 
 
3.1.7 Niosomes as drug carriers 
Niosomes are very promising carriers for the delivery of numerous pharmacological and 
diagnostic agents. A number of publications have reported the preparation, 
characterization, and use of niosomes as drug carriers. Because of their nonionic nature, 
they offer excellent biocompatibility and low toxicity. The unique structure of niosomes 
allows the development of effective novel drug delivery systems with ability of loading 
both hydrophilic and lipophilic drugs. Hydrophilic drugs and lipophilic drugs are 
entrapped into the aqueous core and membrane bilayer of niosome respectively (Figure 
3.2). 
 
 
Figure 3.2 Niosomes in drug delivery 
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Anticancer drug delivery 
The current treatment for cancer is usually chemotherapy. The therapeutic efficacy of 
many anticancer drugs is limited by their poor penetration into tumor tissue and by their 
severe side effects on healthy cells. Various attempts have been made to overcome these 
drawbacks, including the use of niosomes as a novel drug delivery system. 
 
Melanoma 
Artemisone is a 10-amino-artemisinin derivative exhibiting antimalarial activity and also 
possessing antitumor activity. Dwivedi et al. encapsulated artemisone in niosomes using 
thin-film hydration method. The formulations showed highly selective cytotoxicity 
towards the melanoma cells with negligible toxicity towards the normal skin cells [85]. 
5-Fluorouracil (5-FU), largely used in the treatment of different forms of skin cancers, 
was encapsulated in an innovative bola-niosomal system made up of 𝛼,𝜔-hexadecyl-bis-
(1-aza-18-crown-6) (bola-surfactant), Span 80, and cholesterol. The percutaneous 
permeation of 5-FU-loaded bola-niosomes was evaluated by using human stratum 
corneum and epidermis membranes. Bola-niosomes provided an increase of the drug 
penetration of 8- and 4-fold with respect to free drug aqueous solution [13]. The use of 
cisplatin is limited due to its severe toxic effects. Gude et al. synthesized niosomal 
cisplatin by using Span 60 and cholesterol and investigated the antimetastatic activity in 
experimental metastatic model of B16F10 melanoma. Their results suggest that cisplatin 
encapsulated in niosomes has significant antimetastatic activity and reduced toxicity 
when compared to free cisplatin [86]. 
 
Breast cancer 
5-FU-loaded polyethylene glycol- (PEG-) coated and uncoated bola-niosomes were 
prepared by Cosco et al. and were tested on breast cancer cell lines (MCF-7 and T47D). 
Both bola-niosome formulations provided an increase in the cytotoxic effect with respect 
to the free drug. In vivo experiments on MCF-7 xenograft tumor SCID mice models 
showed a more effective antitumor activity of the PEGylated niosomal 5-FU at a 
concentration ten times lower (8 mg/kg) than that of the free solution of the drug (80 
mg/kg) after a treatment of 30 days [87]. Cantharidin entrapped niosomes were prepared 
by injection method. Their potential in enhancing the antitumor activities of the drug and 
reducing its toxicity was evaluated on human breast cancer cell line MCF-7. Moreover, 
in vivo therapeutic efficacy was investigated in S180 tumor-bearing mice. Mice treated 
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with 1.0 mg/kg niosomal cantharidin showed the most effective antitumor activity, with 
an inhibition rate of 52.76%, which was significantly higher than that of the same 
concentration of free cantharidin (1.0 mg/kg, 31.05%) [88]. Recently, tamoxifen citrate 
niosomes were prepared by film hydration technique for localized cancer therapy through 
in vitro breast cancer cytotoxicity as well as in vivo solid antitumor efficacy. The 
optimized niosomal formulation of tamoxifen showed significantly enhanced cellular 
uptake (2.8-fold) and exhibited significantly greater cytotoxic activity on MCF-7 breast 
cancer cell line. In vivo experiments showed enhanced tumor volume reduction induced 
by niosomal tamoxifen when compared to free tamoxifen [89]. 
 
Ovarian cancer 
Uchegbu et al. prepared doxorubicin loaded niosomes. The activity of doxorubicin in 
hexadecyl diglycerol ether (C16G2) and Span 60 niosomes was studied against a human 
ovarian cancer cell line and its doxorubicin resistant subline. According to the results, 
there was a slight reduction in the IC50 against the resistant cell line when the drug was 
encapsulated in Span 60 niosomes in comparison to the free drug in solution [90]. 
 
Lung cancer 
Adriamycin was encapsulated into the niosome using a monoalkyl triglycerol ether by 
Kerr et al. and the activity of niosomal adriamycin compared with free adriamycin 
solution on human lung tumor cells grown in monolayer and spheroid culture and in 
tumor xenografted nude mice. The growth delay (i.e., the time taken the tumor volume 
to double) was significantly longer for adriamycin (15 days) and niosomal adriamycin 
(11 days) than for control (5.8 days). It is possible that the therapeutic ratio of adriamycin 
could be further enhanced by administration in niosomal form [91]. In another study, 
pentoxifylline loaded niosomes were prepared by lipid film hydration method. 
Intravenous administration of niosomal pentoxifylline (6 mg/kg and 10 mg/kg) resulted 
in significant reduction in lung nodules in an experimental metastatic B16F10 model 
suggesting accumulation of pentoxifylline in a distant target. Light microscopic 
observation of histologic sections showed a decrease in number of tumor islands in the 
lung [92]. 
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Targeted delivery  
The efficiency and particularly the specificity of cellular targeting of niosomal drug 
delivery systems can be further improved by active targeting for tumor therapy, by using 
a ligand coupled to the surface of niosomes, which could be actively taken up, for 
example, via a receptor-mediated endocytosis. Niosome surfaces can be conjugated with 
small molecules and/or macromolecular targeting ligands to enable cell specific targeting 
[93]. Proteins and peptides, carbohydrates, aptamers, antibodies, and antibody fragments 
are the most commonly used molecules that bind specifically to an overexpressed target 
on the cell surface [94–96]. Bragagni et al. developed brain targeted niosomal 
formulation using with the glucose derivative as a targeting ligand. They formulated 
niosomal doxorubicin composed of span: cholesterol: solulan: Npalmitoylglucosamine. 
Preliminary in vivo studies in rats showed that intravenous administration of a single dose 
of the developed targeted-niosomal formulation with respect to the commercial one was 
able to significantly reduce the hearth accumulation of the drug and to keep it longer in 
the blood circulation and also to allow the achievement of well detectable doxorubicin 
brain concentrations [30]. Moreover, an efficient tumor-targeted niosomal delivery 
system was designed by Tavano et al. Niosomes were prepared from a mixture of 
Pluronic L64 surfactant and cholesterol and doxorubicin was entrapped into the niosome. 
After the preparation, transferrin was conjugated to niosomes surface using EDC (N-[3-
(dimethylamino)propyl]-Nethylcarbodiimide hydrochloride) chemistry. Doxorubicin 
loaded niosome anticancer activity was achieved against MCF-7 and MDA-MB-231 
tumor cell lines, and a significant reduction in viability in a dose and time-related manner 
was observed [24].The information about some recent studies on niosomal targeted drug 
delivery is summarized in Table 3.2. 
 
Table 3.2 Niosomes in targeted drug delivery 
Targeted 
Tissue 
Loaded 
Therapeutic 
Agent 
Composition Preparation 
Method 
Surface 
Modification 
Targeting 
Molecule 
References 
Brain Doxorubicin Span 60, 
cholesterol, 
solulanC24 and 
N-palmitoyl 
glucosamine 
 
TLE-paddle 
method 
- N-palmitoyl 
glucosamine 
[86] 
 Dynorphin-
B 
Span 60, 
cholesterol, 
solulanC24 and 
N-palmitoyl 
glucosamine 
Sonication - N-palmitoyl 
glucosamine 
[26] 
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 Vasoactive 
intestinal 
peptide 
Span 60, 
cholesterol, 
solulanC24 and 
N-palmitoyl 
glucosamine 
 
Sonication - N-palmitoyl 
glucosamine 
[87] 
Breast cancer Doxorubicin Oxidate 
pluronic L64, 
cholesterol 
 
Thin-film 
hydration 
EDC 
Chemistry 
Transferrin [24] 
Chronic 
myelogenous 
leukemia 
Doxorubicin 
  
Tween60, 
pluronic L64 
Thin-film 
hydration 
- Magnetite [88] 
Epidermoid 
carcinoma 
Hydroxyca
mptothecin 
Span 60, 
cholesterol 
Thin-film 
hydration 
Periodate 
oxidation 
Transferrin  [89] 
 Doxorubicin Span 60, 
cholesterol, 
solulanC24 and 
N-palmitoyl 
glucosamine 
 
Sonication  - N-palmitoyl 
glucosamine 
[90] 
Melanoma Doxorubicin  Span 60, 
cholesterol, 
dicetyl 
phosphate, 
N-lauryl 
glucosamine 
 
Ethanol 
injection 
method 
- N-lauryl 
glucosamine 
[91] 
 
Co-drug delivery  
In recent years, nanoparticles have emerged as a promising class of carriers in co-delivery 
of multiple drugs for combination therapy [97]. Combinational therapies enhance 
therapeutic efficacy and decrease dosage while obtaining equal or greater levels of 
efficacy and reducing drug resistance [98]. Anticancer drugs often have serious side 
effects. With multidrug delivery system Pasut et al. achieved higher anticancer activity 
for carcinoma cells, whereas multi drug delivery system decreased cytotoxicity against 
endothelial cells and cardiomyocytes, with respect to free drug treatment. In their system, 
they have developed simultaneous anticancer drug epirubicin and nitric oxide carrying 
system, in which nitric oxide and epirubicin were covalently conjugated to each terminal 
of PEG. Nitric oxide acts as not only protecting reagent against anthracycline induced 
cardiomyopathy but also sensitizer of anticancer drug treatment. In order to increase 
anticancer efficacy and enhance cardiocyte protecting ability of co-delivery system, they 
used branched PEG as polymer backbone instead of linear one [99]. Multidrug resistance 
(MDR) of malignant neoplasm is the survival ability of cancer cells under the treatment 
with structurally and functionally diverse anticancer drugs. Increased drug efflux is 
mostly mediated by ATP-driven extrusion pump proteins of the ATP-binding cassette 
(ABC) superfamily, such as P-glycoprotein (P-gp) encoded by MDR-1, multidrug 
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resistance (MDR) proteins (MRPs/ABCC) and breast cancer resistance protein 
(BCRP/ABCG2). These drug efflux pumps noticeably decrease the intracellular 
concentration of numerous therapeutic agents [100]. Chemosensitizers, such as 
Verapamil, Elacridar, Tariquidar, and cyclosporine A mainly act as antagonist for P-gp 
and suppress drug efflux and consequently recover chemosensitivity of MDR cancer 
cells. Paclitaxel was co-encapsulated with cyclosporine A within actively targeted 
polymeric lipid-core micelles. P-gp inhibition with cyclosporine A caused an enhanced 
cytotoxicity of paclitaxel. Micelles loaded with this dual cargo demonstrated 
significantly higher cytotoxicity in the MDCKII-MDR1 cells than micelles loaded with 
paclitaxel alone [101]. Niosomes are promising nanocarriers in multi drug delivery 
applications [102]. Recently Sharma et al. reported the dual encapsulation of 
hydrophobic curcumin and hydrophilic doxorubicin in niosomes for cancer multi drug 
delivery [44]. Results showed that dual-drug loaded niosomes had higher cytotoxicity on 
HeLa cells when compared to free drugs. In another study, gallic acid, ascorbic acid, 
curcumin, and quercetin were encapsulated into the niosome as single agents or in 
combination and the effect of the drugs co-encapsulation on the physicochemical 
properties of the carriers, on their antioxidant properties and capability to release the 
encapsulated materials, was evaluated [103]. Furthermore, Marianecci et al. prepared, 
characterized, and applied multi drug niosomes using lidocaine and ibuprofen. Results 
suggest the potential application of niosomes in dermal administration of the two drugs 
at the same time in the same pharmaceutical formulation, as useful carriers for the 
treatment of various skin diseases, such as acute and chronic inflammations in presence 
of pain [104]. 
 
Antibiotics 
Niosomal carriers are also suitable for the delivery of antibiotics and anti-inflammatory 
agents. These carriers have been used extensively to improve poor skin penetration and 
as well as enhance skin retention of the drugs. Begum and coworkers designed 
rifampicin, a broad spectrum antibiotic, encapsulated in a niosomal delivery system.They 
investigated the activity of this system in in vitro conditions and this study showed that 
niosomal formulation of rifampicin is able to provide consistent and prolonged release 
of the drug [105]. In another study to increase efficacy of the antibiotics and reduce the 
dose, Akbari et al. synthesized ciprofloxacin loaded niosomes using different nonionic 
surfactants and cholesterol in various concentrations by film hydration method. Drug 
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release through bilayers and antibacterial activity of the niosomes were examined. The 
results showed that cholesterol content and phase transition temperature of the 
surfactants influenced the performance of niosomes. Besides, all formulations presented 
more antibacterial activity as compared to free ciprofloxacin [106]. Vesicular systems, 
niosomes and liposomes, are mostly used in ophthalmic controlled delivery. Abdelbary 
and El-Gendy examined the feasibility of the niosomes as a carrier for the ophthalmic 
controlled delivery of gentamicin antibiotic. Various surfactants (Tween 60, Tween 80, 
or Brij 35) were combined with cholesterol and a negative charge inducer dicetyl 
phosphate in different molar ratios. The ability of these vesicles to entrap the selected 
drug was evaluated and the obtained results showed that entrapment efficiency and the 
release rate of gentamicin is affected by cholesterol content, type of surfactant, and the 
presence of charge inducer. Gentamicin loaded niosomes composed of Tween 60, 
cholesterol, and dicetyl phosphate were the most effective in terms of prolongation of in 
vitro drug release [107]. 
 
Anti-inflammatory drugs  
Nonsteroidal anti-inflammatory drugs (NSAIDs) loaded niosomes have been prepared 
by several groups. These drugs may cause adverse effects such as mucosal irritation. 
Topically applied NSAIDs loaded niosomes can substantially improve drug permeation. 
To investigate the potential application of the niosomes for delivery of anti-inflammatory 
agents, Marianecci et al. synthesized ammonium glycyrrhizinate (AG) loaded niosomes 
using several surfactants and cholesterol at various concentrations. Drug entrapment 
efficiency, anisotropy, cytotoxicity and skin tolerability, and some further analysis have 
been performed for characterization. The AG-loaded niosomes demonstrated no toxicity 
and good skin tolerability and were able to improve the anti-inflammatory activity in 
mice. Moreover, an enhancement of the anti-inflammatory activity of the niosome 
delivered drug was observed on chemically induced skin erythema in humans [7]. 
 
Antiviral drugs 
Niosomes have also demonstrated the capability to deliver various antiviral agents. 
Ruckmani and Sankar synthesized zidovudine, which is the first anti-HIV compound 
approved for clinical use, encapsulated niosomes, and examined their entrapment 
efficiency and as well as sustainability of release. The niosomes were formulated by 
combining the proportions of Tween, Span, and cholesterol. Niosomes composed Tween 
Theoretical Background 
21 
 
80 entrapped large amounts of zidovudine and the addition of dicetyl phosphate enhanced 
drug release for a longer time [108]. The drug leakage from Tween 80 formulations 
stored at room temperature was significant compared to niosomes stored at 4∘C for 90 
days. Besides, the results of a pharmacokinetic study in rabbits also confirmed that 
Tween 80 formulations with dicetyl phosphate were cleared from the circulation within 
five hours [109]. 
 
3.1.8 Recent studies 
Over the past three decades, niosomes have been successfully used as drug carriers to 
overcome some major biopharmaceutical problems such as insolubility, side effects, and 
poor chemical stability of drug molecules [110]. Table 3.3 summarizes the most recent 
applications of niosomes as drug delivery systems. 
 
Table 3.3 Recent studies on niosomes in drug delivery 
Type of the 
Drug 
Name of the 
Drug  
Composition Experimental Model Year References 
Angiotensin 
receptor 
blockers 
Candesartan 
cilexetil 
Span60, 
cholesterol, 
dicetyl 
phosphate, 
maltodextrin 
In vitro dissolution test for 
proniosomal tablets, in vivo 
evaluation of proniosomal 
tablets, pharmacokinetic 
analysis 
 
2016 [106] 
Anti-
inflammatory 
Naproxen Tween80, 
tween20, 
cholesterol 
In vitro drug release study, 
preformulation study 
 
2016 [107] 
 Dexamethasone Span60, 
cholesterol 
Characterization of niosomes, 
in vitro release studies, stability 
test 
 
2015 [108] 
Anti-bacterial Moxifloxacin 
 
 
Tween60, 
cholesterol 
In vitro release studies, 
antimicrobial activity 
2016 [109] 
 Cefixime C-glycoside 
derivative 
surfactant, 
cholesterol 
In vitro release study, 
biocompatibility and 
bioavailability studies using 
experimental animals 
 
2016 [21] 
Anti-cancer Doxorubicin Span60, 
cholesterol, 
dicetyl 
phosphate, 
N-lauryl 
glucosamine 
Optimization studies for 
formulation, skin irritancy and 
histopathological investigation 
of rat skin 
2016 [91] 
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 Paclitaxel Span40, 
cholesterol, 
dicetyl phosphate 
 
Formulation studies, 
Pharmacokinetic and tissue 
distribution studies 
 
2015 [6] 
Anti-viral  Nevirapine Tyloxapol, 
cholesterol 
 
Diffusion kinetics of drug, 
microviscosity studies, in vitro 
release study 
 
2015 [8] 
H2 receptor 
antagonist 
Famotidine Span60, 
cholesterol 
Kinetic analysis of drug-release 
profiles, ex vivo permeability 
study 
2016 [110] 
 
3.1.9 Strengths and limitations of niosomes in drug delivery 
One of the most important strengths of niosomes compared with liposomes is their 
chemical stability. Niosomes are more stable against chemical degradation or oxidation 
and have long storage time compared to liposomes [51].The surfactants, which are used 
for niosomes preparation, are biodegradable, biocompatible, and nonimmunogenic [83]. 
Handling and storage conditions of surfactants do not need any specifications. Moreover, 
composition, size, lamellarity, stability, and surface charge of niosomes can be controlled 
by the type of preparation method, surfactant, cholesterol content, surface 
charge additives, and suspension concentration [66]. On the other hand, niosomes show 
physical stability problems. During storage of dispersion niosomes are at risk of 
aggregation, fusion, drug leakage, or hydrolysis of encapsulated drugs. Furthermore, the 
sterilization of niosomes needs much effort. Heat sterilization and membrane filtration 
are unsuitable for niosomes. Thus, these areas need further research to produce 
commercially niosomal preparations. 
 
3.1.10 Conclusion 
Niosomes are novel nano drug carriers to design effective drug delivery systems. They 
offer a great opportunity for loading hydrophilic, lipophilic drugs, or both drugs together. 
Numbers of studies have been performed with different types of niosomes in delivery of 
the anticancer agents, anti-inflammatory agents, anti-infective agents, and so forth. The 
relevant studies demonstrated that niosomes improve the stability of the entrapped drug, 
reduce the dose, and enable targeted delivery to a specific type of tissue. The structural 
properties and characteristics of the niosomes can be enhanced by using novel 
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preparations, loading, and modification methods for particular routes of administration. 
Thus, niosomes present itself as promising tools in commercially available therapeutics. 
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3.2 Book Chapter - Niosomes for brain targeting 
This chapter has been submitted as D. Ag Seleci, M .Seleci, R. Jonzcyk, F. Stahl, and T. 
Scheper, Niosomes for Brain Targeting, Carriers for Brain Targeting, Apple Academic 
Press, (accepted 07 September 2017). 
 
3.2.1 Summary 
Several nanocarriers have been used in drug delivery applications tracking the progress 
in nanotechnology. One of the main purposes of using these structures is to overcome 
the current limitations such as poor penetration through the blood brain barrier (BBB) 
and lack of specificity of conventional therapies for brain targeting. A number of 
comprehensive studies have been carried out with niosomes, non-ionic surfactant 
vesicles as a drug carrier. High chemical stability and relatively low cost of the materials 
for niosome preparations make them promising candidates to produce commercial 
products for brain delivery.  
This chapter focuses on design and application potential of niosomal carriers for brain 
targeting. In the introduction part, the difficulties that have been encountered to penetrate 
the BBB in the treatment of central nervous diseases and the properties of the niosomes 
are presented. Afterward, the role of coating the nanoparticles surfaces with non-ionic 
surfactants to facilitate crossing the BBB is discussed. Brief information about structure 
and preparation methods of niosomes is provided. Physicochemical characterization 
parameters of niosomes and the techniques to determine these parameters are reviewed. 
The application potential of niosomes in drug delivery and brain targeting is discussed. 
Moreover, two different targeting strategies (active and passive) to enhance the 
specificity of cancer therapy are described. Especially, the most commonly used active 
targeting ligands for brain targeting are listed. The combination of niosomal drug 
delivery systems with active targeting ligands for the specific delivery of drugs to the 
brain is evaluated in detail.  
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3.2.2 Abstract 
Delivering drug to the brain has still many obstacles. Especially crossing the brain 
barriers is a big challenge. The application of nanomaterials to medicine has provided 
the development of novel drug carriers, can facilitate the delivery of drugs to the brain. 
Niosomes are non-ionic surfactant based vesicles and has been used as a nanocarrier for 
different types of drugs. Moreover, niosome surfaces can be modified with targeting 
ligands to enable cell specific targeting. Due to these promising features, niosomes have 
a great potential using as a carrier for the delivery of drugs to the brain. The present 
chapter provides the fundamental information about niosomal drug delivery systems and 
their recent applications brain targeting.  
 
3.2.3 Introduction  
A number of impediments are present for the effective treatment of central nervous 
system (CNS) diseases. The blood–brain barrier (BBB), which plays a key role in 
protecting and maintaining the homeostasis of the brain, prevents most drugs from 
entering the CNS from the bloodstream. Additionally, the blood-cerebrospinal fluid 
barrier (BCSF) and other specialized CNS barriers hinder efficient delivery of 
therapeutic and diagnostic agents to diseased areas of the brain. Recent advances in 
nanotechnology caused a growing interest using nanomaterials in medicine to solve a 
number of problems associated with BBB [1]. The development of a wide range of 
nanomaterials provides many advantages and new scientific approaches in CNS disease 
diagnosis, treatment, monitoring, and prevention. Multifunctional nanomaterials are able 
to penetrate the BBB and can be easily modified by active and passive targeting to 
enhance the concentration of the drug molecule inside the specific area of the brain [2]. 
Furthermore, the drug is protected by nanocarrier from degradation and/or interaction 
with the biological environment, before reaching the target tissue [3].  
Among various nanocarriers, vesicular systems have received growing attention in the 
recent years for brain drug delivery [4]. They can enhance bioavailability of encapsulated 
drug and provide therapeutic activity in a controlled manner for a prolonged period. 
Niosomes (non-ionic surfactant vesicles) are one of the promising vesicular drug carriers 
that have a bilayer structure and are assembled by self-association of non-ionic 
surfactants in an aqueous phase. In recent years, a variety of non-ionic surfactants has 
been described to form niosomes and enable the encapsulation of numerous drugs with 
a wide range of solubility [5-7]. The non-ionic nature of non-ionic surfactants offers high 
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biocompatibility and low toxicity that are important parameters for drug delivery 
applications. Moreover, niosomes can be produced with lower costs, and have greater 
stability, longer shelf life and wider formulation versatility in comparison with traditional 
liposomes. These superiorities and advantages of niosomes, compared to other drug 
delivery devices, make them promising tools for brain targeting to produce commercially 
available therapeutics.  
This chapter describes the using of niosomes as potential drug delivery systems and 
provides up to date information regarding recent applications of niosomes for brain 
targeting.  
 
3.2.4 Non-ionic surfactants: Enhanced penetration through Bbb  
Non-ionic surfactants are amphiphilic molecules that are composed of two different 
regions: one of them is hydrophilic (water-soluble) and the other one is hydrophobic 
(organic-soluble). They are a class of surfactants that have no charged groups in their 
hydrophilic heads. Alkyl ethers, alkyl esters, alkyl amides, and fatty acids are the main 
non-ionic surfactant classes used for niosome production. They are generally less toxic, 
less hemolytic and less irritating to cellular surfaces compared to their anionic, 
amphoteric, or cationic counterparts. Non-ionic surfactants are used extensively in the 
chemical industry in such areas as detergents, health and personal care, coatings and 
polymers as solubilizers, wetting agents, emulsifiers, and permeability enhancers [8].  
Apart from being a part of niosomes, surfactants play a key role in coating of the 
nanoparticle surface. Surface modifications lead to an increase of nanocarrier circulation 
time in the blood and facilitate penetration of nanoparticles through the BBB via 
recognizing cellular receptors [9]. Especially polysorbate 80 (Tween 80) coated 
nanoparticles are able to transport the loaded drugs across BBB, which cannot cross the 
BBB without Tween 80 [10-12]. First in vivo experiments were performed by Kreuter et 
al. to enlighten the mechanism of this transport system [13]. They investigated the 
possible involvement of apolipoproteins that bind to lipoprotein receptors on the brain 
capillary endothelial cells, in the transport of nanoparticle-bound drugs into the brain. 
Different apolipoproteins were adsorbed directly onto uncoated or Tween 80-precoated 
dalargin-loaded poly(butyl cyanoacrylate) (PBCA) nanoparticles. After intravenous 
injection of these samples to mice, the antinociceptive effect was measured. Results 
showed that especially apolipoproteins E and B yielded high antinociceptive effects that 
were similar to Tween 80-coating alone and even higher after Tween 80 coating plus 
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apolipoprotein E and B overcoating. According to results, it was concluded that the 
Tween 80-coated PBCA nanoparticles adsorb apolipoproteins E and B from the blood, 
and these proteins stimulate receptor-mediated endocytosis of the particles by the 
endothelial cells forming the BBB. Moreover, coating PBCA with the non-ionic 
surfactant poloxamer 188 also enhanced the antitumor action of doxorubicin against 
intracranial glioblastoma [14, 15]. Consequently, these systems facilitate the delivery of 
the drug into the brain. 
 
3.2.5 Niosomes: Structure, preparation, and characterization  
Niosomes are primarily composed of non-ionic surfactants, cholesterol and hydration 
medium. The self-assembly of non-ionic surfactants in aqueous media results in the 
formation of closed bilayered vesicles. Application of additional energy such as 
mechanical (physical shaking, ultrasound) or heat is needed for the formation of 
niosomes. Cholesterol interacts with non-ionic surfactants via hydrogen bonds in the 
bilayer and plays an important role in the physical properties and structure of niosomes. 
It prevents the vesicle aggregation and improves the rigidity of niosomes [16]. Besides, 
charged molecules such as dicetyl phosphate, phosphatidic acid and stearylamine are 
added to the bilayer to increase the stability of vesicles [17]. The addition amount of 
charged molecule to niosomal formulation needs to be 2.5–5.0 mol%. Adding the high 
amount of charged molecules may inhibit niosome formation. These vesicles can be 
categorized into three groups according to their size and number of bilayers: small 
unilamellar vesicles (SUV, 10–100 nm), large unilamellar vesicles (LUV, 100–3000 
nm), and multilamellar vesicles (MLV, 1000-more nm) where more than one bilayer is 
present (Figure 3.3). 
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Figure 3.3 Structure and categorization of niosomes 
 
Preparation of niosomes requires simple methods. Preparation techniques comprise generally the 
hydration of a mixture of surfactant/lipid at elevated temperature using hydration medium 
including drug. Subsequently, size reduction methods such as sonication and extrusion are 
applied to obtain a colloidal dispersion. Finally, the unentrapped drug is removed from the 
niosomal dispersion by centrifugation, gel filtration, or dialysis. The well-known protocols for 
niosome preparation are: thin-film hydration [18, 19], ether injection [20], reverse phase 
evaporation [21], trans membrane pH gradient [22] and proniosome [23].  
Physicochemical characterization parameters of niosomes are vesicle size, morphology, 
size distribution, zeta potential, number of lamellae. These parameters have a direct 
impact on the stability of niosomes. The characterization methods of niosomes are 
summarized in Table 3.4. Furthermore, entrapment efficiency (EE%), stability and drug 
release are critical factors for medical applications of niosomes. EE% is the percentage 
of the drug entrapped in niosomes referred to the initial amount of drug that is present in 
the non-purified sample. It is affected by niosome contents, physicochemical properties 
of drug, and preparation methods [24]. The stability of niosomes can be tested by 
measuring mean vesicle size and size distribution or determining the entrapment 
efficiency over several month storage periods at different conditions. Sustained drug 
release from niosomes is another quite important issue to minimize side effects of the 
drug in the human body and enhance the effects of drug at the target location. The release 
rate of the drug from niosomes is generally determined via dialysis method. 
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Table 3.4 Characterization methods of niosomes 
Parameters  Methods used to determine the parameter References 
Size and 
morphology 
Dynamic light scattering (DLS), Nanoparticle tracking 
analysis (NTA), Transmission electron microscopy 
(TEM), Scanning electron microscopy (SEM), Cryo-
transmission electron microscopy (cryo- TEM), Atomic 
force microscopy (AFM) 
[25-28] 
Size distribution DLS [5] 
Surface charge 
and zeta potential 
Zetasizer, Microelectrophoresis, DLS, pH-sensitive 
fluorophores 
[29] 
Bilayer 
characteristics  
Small angle X-ray scattering (SAXS), In situ energy-
dispersive X-ray diffraction (EDXD) 
[25,30] 
 
3.2.6 Niosomal drug delivery systems  
Side effects, poor solubility and chemical stability are the main problems of conventional 
drugs passing through different environments in the human body on their way to the 
target location. These cause inefficient therapeutic effect. Niosomes have been used for 
the delivery of several pharmacological and diagnostic agents to overcome these 
problems. Due to their biocompatibility, low toxicity, and unique structure, they allow 
the development of effective novel drug delivery systems [31]. They are able to load both 
hydrophilic and lipophilic drugs. Hydrophilic drugs are encapsulated into the aqueous 
core and lipophilic drugs are incorporated in the membrane bilayer of niosome. 
Moreover, they offer a great opportunity for loading both drugs together in one 
nanocarrier (Figure 3.4). Another feature of the niosomes is the fluidity of their 
membrane, which allows the controlled release of a compound without destroying the 
vesicular structure. The drug release occurs by passive transport of the drug through the 
niosomal membrane bilayer. Physicochemical parameters of niosomes can be arranged 
to obtain the desired drug delivery system. Besides, the surface of niosomes can be easily 
modified to create targeted niosomes.  
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Figure 3.4 Encapsulation drugs in niosome 
 
The application of niosomal technology is widely varied and can be used to treat a 
number of diseases. They have been used in pulmonary delivery [32], transdermal 
delivery [33], ophthalmic delivery [34], vaccine delivery [35], gene delivery [36], protein 
and peptide delivery [37] and delivery of chemotherapeutics. The concept of loading 
anti-cancer drugs into niosomes for a better delivery of the drug to specific target location 
is widely investigated by researchers. Anti-cancer drugs such as doxorubicin [38, 39], 
paclitaxel [27], methotrexate [40], 5-fluorouracil [41] were successfully entrapped in 
niosomes and characterized in detail to develop efficient drug carrier systems for cancer 
therapy. To test the efficiency and specificity of niosomal anti-cancer drugs, in vitro and 
in vivo investigations were performed [42, 43]. Results from a number of studies suggest 
that niosomes have great potential in the application of several types of cancer therapy 
[44, 45]. Furthermore, antibiotics [46], anti-inflammatory [47], and antiviral drugs were 
entrapped in niosomes to improve their stability and reduce the dose of the drug.  
 
3.2.7 Targeting strategies  
Transporting of drugs to the target site is a major drawback in the treatment of many 
diseases. Numbers of conventional drugs have limited effectiveness, poor biodistribution 
and a lack of selectivity. Especially, effective and specific delivery of drugs to the brain 
is a big challenge since most drugs cannot pass the BBB. Nanoparticles are promising 
tools to deliver drugs to the desired part of the body. There are two different strategies 
for targeting of the nanoparticles: passive and active targeting. 
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Passive targeting  
Tumor tissue has highly disorganized vascular architecture, irregular blood flow, and 
reduced lymphatic drainage. These properties provide the enhanced permeability and 
retention (EPR) effect for nanoparticles that can enhance the intracellular concentration 
of the drugs in cancer cells. The strength of EPR effect is influenced by two factors. First, 
angiogenic tumors produce vascular endothelial growth factors. These growth factors 
increase the permeability of newly formed vessels associated with the tumor and cause 
infiltration of circulating particles. Second, due to the reduced lymphatic drainage of 
tumors, the permeating nanocarriers are not removed efficiently and thus are retained in 
the tumor tissue, which leads to the accumulation of nanoparticles.  
Passive targeting of nanoparticles also enables the drugs to pass the BBB via different 
pathways [1]. A wide range of CNS drugs may enter into the brain with nanocarriers. 
 
Active targeting  
Active targeting is based on targeting ligands such as antibodies, peptides, aptamers and 
small molecules that bind specifically to an overexpressed target on the cell surface and 
trigger receptor-mediated endocytosis after binding. Nanoparticles are conjugated with 
targeting ligands thereby allowing accumulation of the drug within tissues or intracellular 
organelles specifically.  
Active targeting of the BBB and brain tumors represent a promising non-invasive 
approach for enhanced drug delivery to the brain. The identified and commonly-targeted 
receptors for brain targeting are: transferrin, insulin, low-density lipoproteins (LDL), 
leptin, glutathione, folic acid, and neuropilin. Summary of brain targeting ligands and 
their receptors are listed in Table 3.5. 
 
Table 3.5 Targeting ligands and their receptors for active brain targeting 
Targeting ligand Targeted receptor References 
Folic acid Folate receptor [48,49] 
Transferrin Transferrin receptor (TfR) [50,51] 
Anti-TfR monoclonal antibody 
(mAb), 7579 
TfR [52] 
Angiopep-2 Low-density lipoprotein 
receptor (LDR) 
[53,54] 
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Anti-insulin receptor monoclonal 
antibody (29B4) 
Insulin receptor [55] 
Glutathione Glutathione receptor [56] 
Peptides comprising amino acid 
residues 70–89 of leptin (Lep70–89) 
Leptin receptor (ObR) [57] 
tLyp-1 peptide Neuropilin receptor [58,59] 
 
3.2.8 Niosomes for brain targeting  
In the literature, the advantages of niosomes have been already used to obtain efficient 
delivery of therapeutic agents to the brain. Morin hydrate (MH), which has a 
neuroprotective effect in Parkinson’s disease, was encapsulated in niosomes composed 
of nonionic surfactants, cholesterol and dicetyl phosphate. Niosomal formulations were 
optimized and injected to mouse via lateral tail vein to take real time images. A non-
invasive real-time imaging technique was applied to understand the in vivo 
biodistribution of MH niosomes. The ex vivo imaging of the excised organs demonstrated 
the capability of MH niosomes to cross the BBB [60]. Varshosaz et al. prepared niosomal 
formulation of 𝛼-tocopherol and ascorbic acid for enhanced brain delivery of these drugs 
in preventing neuronal cell damages during ischemia-reperfusion disorders. After 
characterization studies, neuroprotective effects of the niosomal formulations were 
investigated in an ischemiare-perfusion model in male rats. In vivo results showed that 
the effectiveness of the formulated new drug delivery system in protection of cerebral 
tissue against elevation in oxygen free radical concentration during cerebral ischemia-
reperfusion course was more than the free ascorbic acid [61].  
Moreover, delivery of the drugs to the brain via nasal route provides some more 
advantages. Folic acid is a water soluble vitamin having difficulty in crossing the BBB 
and the low blood level of folic acid is the main cause of depression in Alzheimer's 
disease. Ravouru et al. developed niosomal nasal drug delivery systems by using folic 
acid to target the brain. Ex vivo perfusion studies were carried out using a rat model and 
results showed that about 48.15% of the drug was absorbed through nasal cavity at the 
end of 6 hrs [62].  
Recently, niosomes containing cationic lipids were used as a carrier for gene delivery in 
retina and brain. Niosome-DNA vectors (nioplexes) were prepared and characterized in 
detail. In vitro experiments were performed to evaluate transfection efficiency and cell 
viability in different cell lines. Subsequently, nioplexes were administrated to rat retina 
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via intravitreal and subretinal injections and to rat brain with in cerebral cortex. In vivo 
results demonstrated that after injections of nioplexes, the cells in rat retina and brain 
were transfected successfully [63]. 
These outcomes provide new insights for the development of niosome based delivery 
systems for brain targeting. Furthermore, several approaches were used for active 
targeting of the niosomal drugs to the brain that are explained below.  
 
3.2.9 Modification of niosomes with targeting ligands  
 
Glucose derivatives  
The large energetic demand of the brain is provided almost by β-D-glucose. Glucose in 
the blood must cross the BBB's luminal and abluminal membranes to reach neural tissue. 
It is transported to the brain via transporters, enzymes, and cell signaling processes. 
Glucose transporter (GLUT1) enables glucose transport across the BBB and it is 
overexpressed on BBB cells. Therefore, glucose derivatives are promising targeting 
ligands for drug transport through the BBB.  
Dufes et al. synthesized N-Palmitoylglucosamine (NPG, the glucose-derivatized 
surfactant) niosomes entrapping vasoactive intestinal peptide (VIP) by shaking a mixture 
of NPG, non-ionic surfactants (Span 60 and Solulan C24) and cholesterol in PBS at 90 
ºC for 30 min, followed by probe sonication for 5 min [64]. VIP was entrapped into 
niosomes by probe sonicating them in 125I-VIP and unlabelled VIP solution. VIP and 
125I-VIP-loaded glucose-bearing niosomes were intravenously injected to mice. After 
administration of VIP in solution or encapsulated in glucose-bearing niosomes or in 
control niosomes, brain uptake was determined by measuring the radioactivity of 125I-
labeled VIP. Results indicated that VIP encapsulation within glucose-bearing niosomes 
mainly allowed a significantly higher VIP brain uptake compared to control niosomes. 
In another study, Bragagni et al. investigated the development and characterization of a 
niosomal formulation functionalized with NPG to obtain a potential brain targeted 
delivery system for the anticancer drug doxorubicin [65]. The developed doxorubicin 
NPG-niosomal formulation was injected in rats, in comparison with a commercial 
solution of drug in order to evaluate its effectiveness in enhancing doxorubicin brain 
delivery. After administration, significantly higher doxorubicin plasma levels were 
obtained with the NPG-niosomal dispersion with respect to the commercial solution at 
the same drug dosage. Their results showed that the developed niosomal formulation was 
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able to keep the drug longer in the blood circulation system compared to the commercial 
drug solution. Moreover, NPG functionalized niosomal formulation was also used to 
targeted delivery of dynorphin-B, which is an endogenous neuropeptide with relevant 
pharmacological activities on the central nervous system [66]. The optimized niosomal 
formulation with entrapped dynorphin-B was administered intravenously to mice. The 
antinociceptive effect of this niosomal formulation and a simple solution of the peptide 
were investigated. A significantly higher antinociceptive effect was obtained for targeted 
niosomal dynorphin-B, than for peptide solution. It can be concluded that encouraging 
and promising results were obtained in the previous studies by using niosomes bearing 
NPG as a drug carrier and this may trigger the usage of this system in further studies.  
 
Transferrin  
Transferrin receptor, which is an iron binding transmembrane protein and facilitates iron 
uptake in cells, is highly expressed in brain endothelial cells. Several types of 
nanoparticles were functionalized with TfR binding ligands such as peptides [67], 
antibodies [68], or transferrin [69] to deliver therapeutics to the brain.  
TfR is also overexpressed in tumor cells. Niosomes were coupled with transferrin to 
improve tumor therapy. Hydroxycamptothecin (HCPT) was loaded into polyethylene 
glycolated niosomes (PEG-niosomes) and transferrin was conjugated to the surface of 
PEG-niosomes. Compared with HCPT injection, transferrin conjugated PEG-niosomes 
demonstrated stronger anti-tumor activity in mice [70]. In another study, niosomes were 
prepared from Pluronic L64 surfactant and cholesterol by Tavano et al. After the 
preparation, transferrin was conjugated to niosomes and rhodamine was loaded the 
vesicles. The specific uptake of rhodamine-loaded transferrin conjugated-niosomes was 
evaluated on tumor cells via confocal microscopy. Results demonstrated that transferrin 
conjugated-niosomes were specifically uptaken by tumor cells [71]. However, 
transferrin-bearing niosomes have not been applied for brain targeting yet, they have a 
great potential for future studies.  
 
tLyP-1 peptide  
Neuropilin-1 (NRP-1) is a transmembrane protein overexpressed on the surface of both 
glioma and endothelial cells of angiogenic blood vessels [72-74]. tLyp-1 (tumor homing 
and penetrating peptide) peptide with 7 amino acid (CGNKRTR), is as a ligand targeted 
to the NRP-1 receptor with high affinity and specificity. Hence, tLyp-1 has been used as 
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a targeting ligand for the delivery of drugs to the brain tumor [58]. Recently, polyethylene 
glycolated niosomes (PEGNIO) were synthesized and doxorubicin and curcumin were 
encapsulated in niosomes via thin film hydration method. The surface of co-drug loaded 
PEGNIO was modified with tLyp-1. After characterization studies, in vitro 
investigations were carried out on human glioblastoma and human mesenchymal stem 
cells. The results clearly indicated that the strategy by co-administration of doxorubicin 
and curcumin with tLyp-1 functionalized niosomes could significantly improve anti-
glioma treatment [75].  
 
3.2.10 Conclusions and future directions  
The treatment of brain related diseases presents a major challenge. Using nanoparticles 
may enable to overcome the difficulties of delivering therapeutic agents to specific 
regions of the brain. Niosomes are one of the promising drug carriers to design novel 
drug delivery systems for brain disease treatment. Their unique structure provides 
loading hydrophilic, or lipophilic drugs, or both drugs together in the same vesicle at the 
same time. Besides, their surface can easily be functionalized and modified with ligands. 
These features of the niosomes have been already applied to deliver different types of 
agents to the brain. However, presently there are no commercial niosomal drugs available 
for brain targeting. Therefore, further research studies needed to be performed. 
Especially, the design of new targeted and co-drug loaded niosomal delivery systems for 
brain targeting may contribute to producing commercially available products.  
 
Key words  
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4. Experimental Investigations 
The purpose of this study is to develop novel niosomal formulations for targeted drug 
delivery and to investigate their application potential under in vitro conditions. For this 
purpose, several targeting moieties including an aptamer and a peptide were combined 
with the drug loaded-niosomes for targeting of cancer cells. The experimental part of this 
dissertation consists of two chapters. In chapter 4.1, PEGylated niosomes, which have 
high stability and bioavailability, were synthesized and characterized. The surface of the 
niosomes was modified with MUC1 aptamer-CysTAT peptide conjugate and their 
applicability for targeted therapy was examined. The second chapter 4.2 aims to develop 
an efficient drug delivery platform specifically for brain tumors. The effects of combined 
loading of curcumin and chemotherapeutic agent to niosomes on glioblastoma were 
investigated by using tumor-homing peptide tLyp-1, which has high affinity and 
specificity to neuropilin receptor (NRP-1).        
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4.1 Aptamer mediated niosomal drug delivery 
The results of this chapter were published as D. Ag Seleci, M .Seleci, A. Jochums, J.G. 
Walter, F. Stahl, and T. Scheper, Aptamer mediated niosomal drug delivery, RSC 
Advances, 2016, 6, 87910- 87918. The article was reproduced with permission of  Royal 
Society of Chemistry.  
 
4.1.1 Summary 
Vesicular nanocarriers such as liposomes and niosomes are remarkable tools for 
nanomedical applications. In general, vesicles composed of phospholipids are called 
liposomes whereas niosomes consist of non-ionic surfactants that are more economical 
and chemically more stable when compared to the phospholipids. Cholesterol can also 
be used to improve membrane rigidity as well as stability. The surface of the 
nanoparticles can be modified with biological molecules to enhance the therapeutic effect 
within the targeted tissue. Moreover, the attachment of polyethylene glycol (PEG) 
molecules to the surface can increase the circulation time in the blood stream long enough 
to allow transport to target tissues by decreasing recognition of nanoparticles by the 
immune system. In the present study, a novel niosomal drug carrier was designed. 
PEGylated niosomes were prepared by the thin film layer hydration technique, using 
Span60, Cholesterol and DSPE-PEG(2000)Maleimide. Cell penetrating peptide 
(CysTAT) and cell specific MUC1 (S2.2) aptamer were conjugated to each other by 
using BS3 homo-bifunctional crosslinker and conjugates were characterized via gel 
electrophoresis as well as HPLC. Then the niosome surface was modified with the 
conjugate, CysTAT-MUC1 to allow active targeting by binding to the target cell surface. 
As a selected model anticancer drug, doxorubicin (DOX) was encapsulated into the 
niosomes. The hydrodynamic size of the niosomes were determined to be approximately 
150 nm with a relatively low polydispersity index (~0.25). After the conjugation of 
CysTAT-MUC1, increasement in size was of around 14 nm was observed. Drug release 
profile was monitored in physiologic pH 7.4 and pH 5.6 to mimic acidic tumor 
microenvironment over 60 h. As expected DOX release was higher at pH 5.6. MUC1 
gene and receptor expression levels of the cells were investigated by PCR and flow 
cytometry, respectively. HeLa (cervical cancer cells) showed considerably higher 
expression levels and were therefore selected as positive cell line, whereas U87 (human 
glioblastoma cells) cell exhibited much lower intensity and were used as a control. 
Cellular uptakes of the niosomal formulations and free dye were evaluated on both cell 
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lines by flow cytometric analysis. DOX loaded targeted niosomes were taken up more 
efficiently by HeLa cells than free DOX after 2 h. However, the uptake level of free DOX 
was higher than for niosomal formulations for U87 cells. The internalization was also 
observed through fluorescence microscopy. The cytotoxicity of niosomal formulations 
and free DOX was investigated via 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
(MTT) assay 24 and 48 h after treatment. According to the results, bare niosomes were 
almost nontoxic to HeLa and U87 cells with relative cell viabilities above 80% for both 
24 and 48 h. The targeted drug-loaded niosomes showed a stronger cytotoxic effect on 
MUC1 receptor overexpressing HeLa cells.      
Overall, the results presented here demonstrate the potential of an aptamer targeted 
niosomal drug delivery system. Biocompatible PEGylated niosomes were synthesized 
with well defined physicochemical properties and their surface was decorated with 
peptide-aptamer conjugate. Taking into account the obtained results, the designed 
platform has an application potential for delivery of agents to MUC1-overexpressing 
tumor cells. 
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4.1.2 Abstract 
Development of nanoscale carrier systems for targeted drug delivery is crucial for cancer 
treatment. The current methods of drug delivery exhibit some problems such as lack of 
therapy efficiency at the desired parts of the body, degradation of the drug before 
reaching the desired tissue and limitations in cellular penetration. In this work, a novel 
drug delivery platform was developed to overcome these problems and to enable specific 
and efficient uptake into the cells. The surface of the synthesized polyethylene glycolated 
niosomes (PEGNIO) was modified with cell penetrating peptide (CPP) and cell specific 
MUC1 (S2.2) aptamer, and doxorubicin (DOX) as a cancer model drug was encapsulated 
in this platform. Fluorescence microscopy and flow cytometry analysis were used to 
investigate the cellular uptake and intracellular distribution of the DOX loaded niosomal 
formulation. In vitro cytotoxicity studies were carried out using MUC1 positive HeLa 
and negative U87 cells. Moreover, dynamic light scattering (DLS), zeta potential 
measurements and fluorescence absorption spectroscopy were performed to determine 
the vesicle size, as well as charge and spectroscopic properties of the conjugates. From 
these results, this novel aptamer mediated niosomal drug delivery platform may have 
application potential in targeted drug delivery towards MUC1-overexpressing tumors. 
 
4.1.3 Introduction 
A drug delivery system (DDS) is described as a formulation that enables the introduction 
of drug molecules into the body with improved efficacy and safety. Due to the rapid 
progress of nanotechnology, numerous nanocarriers have been developed to securely 
deliver drugs into target sites. New targeting agents, including aptamers, short peptides, 
and small molecules have recently become promising targeting ligands to design novel 
drug delivery systems. The current treatment options for cancer are surgical operation, 
radiation and chemotherapy or a combination. The therapeutic efficacy of many 
anticancer drugs is limited by their poor penetration into tumor tissue and by their side 
effects on healthy cells.1 To overcome these limitations, development of a novel carrier 
platform for specific drug uptake into the cell with an optimal dose at high efficiency is 
important. Therefore, anticancer drugs can be conjugated with biomolecules exhibiting 
potential for cellular targeting and penetration and can be delivered to the desired site of 
action by multi-functional carrier platforms. Vesicular nanocarriers have received great 
attention as potential drug carrier systems. Nonionic surfactant based vesicles 
“niosomes” are one class of vesicular nanocarriers which can accommodate a large 
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number of drugs with a wide range of solubility.2–4 Due to their low cost, long term 
storage stabilities and lower toxicity of niosomes have been used for drug delivery.5–7 
The addition of polyethylene glycol (PEG) to the nanocarrier surface increases the steric 
stabilization of the nanoparticle and allows for further surface modifications to design 
specific drug delivery systems. It is generally thought that PEGylation protects the 
delivery systems against the immune system and thereby prolong circulation life times.8 
In solid tumors, the penetration of the tissue by the anticancer drug is limited which 
causes reduced efficacy and the development of drug resistance.9 A promising approach 
to overcome the cellular barrier is based on the use of certain peptides namely cell 
penetrating peptides (CPPs), able to translocate across the cell membrane and deliver 
their payload intracellularly within minutes.10 CPPs consist of small cationic or 
amphipathic peptides that aid the uptake of attached cargos into living cells. A wide 
variety of small molecules and biomolecules including plasmid DNA, siRNA, 
oligonucleotides and peptide nucleic acid molecules have been attached to these peptides 
and were subsequently internalized.11–13 The ability of CPPs to translocate biologically 
active molecules into cells makes these peptides promising candidates for theranostic 
applications.14 TAT is one of the smallest polycationic CPPs composed of arginine and 
lysine residues. Studies on the binding affinities of cationic TAT peptides indicate that 
these peptides strongly bind electrostatically to the various anionic species (e.g. heparan 
sulphate proteoglycans) present at the extracellular surface of cell membranes.15,16 The 
exact molecular mechanism of cellular entry of CPPs is currently not fully understood. 
Former studies indicated that in general uptake occurs by endocytosis (or more 
specifically macropinocytosis) and direct membrane translocation.17 The lack of cell 
specificity remains the major drawback for the clinical application of CPPs.18 Receptors 
that are over-expressed in many cancer cells are suitable targets to achieve a more 
specific delivery. MUC1 is a large transmembrane glycoprotein overexpressed in most 
malignant adenocarcinoma, including ovarian, lung, pancreatic, prostate, and breast 
cancers, making it an ideal target molecule for chemotherapeutics.19 Aptamers are short 
oligonucleotides that are capable to selectively bind their corresponding target.20–22 
These reagents are selected by an in vitro process called SELEX, (systematic evolution 
of ligands by exponential enrichment).23 Several MUC1 aptamers were developed by 
Ferreira et al. and S2.2 is a 25-nucleotide truncated version of the original MUC1 
aptamer. It binds MUC1 protein with high specificity and affinity with a KD of 0.135 
nM.24,25 S2.2 has been used in a few targeted delivery systems. Yu et al. used MUC1 
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aptamer to target paclitaxel (PTX) loaded poly(lactic-co-glycolicacid) (PLGA) 
nanoparticles.26 Furthermore PEG-modified MUC1 targeting doxorubicin (DOX) was 
designed and the aptamer–doxorubicin complex was prepared by intercalation of the 
aptamer with DOX by Tan et al.27 Recently, Liu et al. synthesized vinorelbine (VRL) 
loaded and MUC1 aptamer modified lipid–polymer hybrid nanoparticles.22 In this study, 
polyethylene glycolated niosomes (PEGNIO) were prepared from                                  
span60, cholesterol and 1,2-distearoyl-snglycero-3-phosphoethanolamine-N-  
[maleimide(polyethyleneglycol)-2000] (DSPE-PEG(2000)Maleimide). DOX was 
encapsulated into the PEGNIO. The niosomes were characterized with respect to size, 
morphology and drug encapsulation efficiency. Cysteine-modified cell penetrating 
peptide (CysTAT) was conjugated to the amine group of MUC1 aptamer in the presence 
of a crosslinking agent bis(sulfosuccinimidyl)suberate (BS3). Subsequently, CysTAT–
MUC1 conjugate was attached to DOX encapsulated PEGNIO (PEGNIO/DOX) via the 
formation of a thioether linkage. The anticancer activity of DOX-loaded targeted vesicles 
was studied in HeLa (cervical cancer cells) and U87 (human glioblastoma cells) cell lines 
by evaluating the cellular uptake and cytotoxicity. The designed nanoparticular drug 
delivery system composed of aptamer–CPP–PEGNIO was first fabricated in this study. 
Our findings suggest that this platform can serve as a delivery vehicle for cancer cells 
overexpressing MUC1. 
 
4.1.4 Materials and methods 
 
Materials 
Amine and Cy5 modified MUC1 aptamer S2.2 (50-NH2-GCA GTT GAT CCT TTG 
GAT ACC CTG G-30), (50-Cy5-GCA GTT GAT CCT TTG GAT ACC CTG G-30) 
were purchased from Integrated DNA Technologies. CysTAT with 
CYGRKKRRQRRR–NH2 sequence was obtained from GenScript. DSPE-PEG(2000) 
Maleimide was provided by Avanti. Span60, cholesterol, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazoliumbromide (MTT), 4,6-diamino-2-phenylindol (DAPI) and 
Dulbecco's Modified Eagle Medium (DMEM) were ordered from Sigma Aldrich. 
RNAtidy G and sodium dodecyl sulfate (SDS) were purchased from Applichem. BS3 
was ordered from Covachem. Doxorubicin (hydrochloride) was purchased from Cayman 
Chemical. GeneRuler 100 bp DNA ladder and dNTP Set (100 mM solutions) were 
obtained from Fermentas. M-MLV reverse transcriptase and its M-MLV RT 5-buffer as 
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well as GoTaq polymerase and its 5-Green GoTaq reaction buffer were provided from 
Promega. PCR primers were synthesized by Life Technologies.  
 
Preparation of PEGylated niosomes 
Multi lamellar vesicles (MLVs) of PEGNIO were prepared by the thin film hydration 
method.28 Span 60, cholesterol, and DSPEPEG(2000) Maleimide were dissolved in 1.0 
mL chloroform in a round-bottom flask with the molar ratio of 4.95 mM : 4.95 mM : 0.1 
mM. The solvent was evaporated with constant rotation at 38 °C under reduced pressure 
to form a thin lipid film. Then the thin film was hydrated with 1.0 mL of distilled water 
for preparing empty niosomes, or a doxorubicin solution (0.22x 10-3 M in water) to obtain 
PEGNIO/DOX conjugate at 60 °C for 60 min. Afterward, the niosomal suspension was 
equilibrated at room temperature overnight, to complete annealing and partitioning of the 
drug between the lipid bilayer and the aqueous phase.5 Small unilamellar vesicles (SUVs) 
were prepared starting from MLVs by extruding the niosomes 11 times through 0.4 mm 
and 0.1 mm pore size polycarbonate filters using mini extruder set (Avanti polar lipids). 
Niosomes were purified by dialysis against water for 3 h using 6–8 kDa dialysis bag.  
 
Synthesis and characterization of CysTAT–MUC1 conjugate  
The conjugation between CysTAT and amine modified MUC1 aptamer was performed 
using an amine to amine crosslinker BS3. 35 µL containing 5 nmol amine modified 
MUC1 aptamer, 30 µL containing 20 nmol CysTAT peptide and 150 µL containing 1.75 
mmol BS3 were mixed in 85 µL 0.1 M sodium phosphate including 0.15 M sodium 
chloride at pH 7.4 and incubated at room temperature for 1 h. Once the reaction was 
completed, 300 µL 1.0 M Tris buffer was added to quench the reaction for 20 minutes at 
room temperature. Unreacted peptides and quenched crosslinkers were removed through 
dialysis against PBS (pH 7.2) using 3.5 kDa dialysis bag. During this reaction aptamer–
aptamer and peptide–peptide conjugation can occur. Denaturing urea polyacrylamide gel 
electrophoresis (Urea PAGE) and HPLC were used for the characterization of CysTAT–
MUC1. Urea PAGE was performed according to manufacturer's instructions (QIAGEN). 
Briefly, 15% acrylamide/urea gel was prepared and run for 30 min at 200 V. The samples 
were heated at 95 °C for 2 min and then they were immediately transferred onto ice. The 
samples were loaded onto the gel and the gel was run for 1.5 h at 200 V. Afterward the 
gel was stained with methylene blue solution and documented using an INTAS UV 
documentation system. HPLC measurements and carried out using VWR Hitachi 
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Chromaster. For the analysis, a DAD detector and Kinetix 2.6 mm C8 100 °A, 150x4.6 
mm (Phenomenex) column were used. Detection was performed at 214 nm at room 
temperature. The mobile phase consisted of 0.065% trifluoroacetic acid (TFA) in water 
and 0.05% TFA in acetonitrile with a flow rate of 1.0 mL min-1.  
 
Conjugation CysTAT–MUC1 to PEGNIO/DOX 
CysTAT–MUC1 was conjugated to PEGNIO/DOX via thiol group of cysteine to 
maleimide group on PEGNIO resulting in the formation of a thioether linkage.29,30 
Maleimide group reacts specifically with thiol-groups in the pH range 6.5–7.5. 100% of 
the prepared CysTAT–MUC1 conjugate in PBS (pH 7.2) and 50% of the prepared 
PEGNIO/DOX were mixed and incubated overnight at room temperature. After 
completing the reaction between sulfiydryl group of CysTAT and maleimide group of 
DSPE-PEG(2000) Maleimide, the final PEGNIO/DOX/CysTAT–MUC1 conjugate was 
purified using 14 kDa dialysis bag to remove unbound CysTAT–MUC1. Schematic 
representation of niosome synthesis, drug encapsulation and the bioconjugation 
processes are shown in Scheme 1. 
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Scheme 1. Schematic representation of drug the encapsulation and the bioconjugation process. 
 
Measurement of particle size, distribution and zeta potential 
Size, size distribution and zeta potential of niosomes were determined by dynamic light 
scattering (DLS) analysis using Malvern Zetasizer Nanoseries-Nano-ZS. The 
polydispersity index (PDI) was used as a measure of the width of size distribution. PDI 
less than 0.3 corresponds to a homogeneous population for colloidal systems.31 Each 
sample was measured three times. 
 
Stability 
The stability of DOX loaded niosomal formulations was tested via DLS analysis. After 
the synthesis of PEGNIO/DOX and PEGNIO/DOX/CysTAT–MUC1, these conjugates 
were stored at 4 °C in the dark. The particle size and PDI values were measured for 2 
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months. Additionally, the particle size of PEGNIO/DOX/CysTAT–MUC1 was measured 
in cell culture media before and after the incubation at 37 °C for 24 h. 
 
Entrapment efficiency 
The drug encapsulation efficiency was determined using the dialysis technique.32 
According to this method, directly after the preparation 1.0 mL of PEGNIO/DOX and 
1.0 mL of PEGNIO/DOX/CysTAT–MUC1 dispersions were dropped into two dialysis 
bags (12–14 kDa) and immersed in 100 mL of distilled water with magnetic stirring at 
100 rpm. Samples were dialyzed for 3h. The percent of encapsulation efficiency (E%) 
was expressed as the percentage of the drug entrapped in niosomes (and thus not removed 
via dialysis) referred to the initial amount of drug that is present in the nondialyzed 
sample. It was determined by diluting 50 µL of dialyzed and 50 µL of nondialyzed 
niosomes in 1.0 mL of methanol. This step is essential for breaking the niosomal 
membrane, thereby releasing the entrapped DOX. Subsequently, the amount of DOX was 
determined by HPLC using a C18 column (Phenomenex Kinetix, 4.6 x100 mm, 2.6 mm) 
at 35 °C and a UV detector was conducted at 254 nm. The mobile phase consisted of 
methanol and water (60/40, v/v) containing 0.1% formic acid and 0.1% ammonia 
solution (25%) with a flow rate of 1.0 mL min-1.33 The stock solutions of DOX were 
prepared at 1.0 mg mL-1 in methanol and further diluted with methanol in the 
concentration range 1.0–200 µgmL-1. The amount of encapsulated DOX was calculated 
according to the calibration curve (y = 120 777x - 67 040, R2 = 0.9984). The limit of 
detection (LOD) and limit of quantification (LOQ) for DOX were found to be 6.12 
µgmL-1, 18.55 µgmL-1 respectively based on 3.3σ/slope and 10σ/slope formulations.34 
 
Drug release 
Drug release experiments were performed using the dialysis method. The DOX-loaded 
niosome solutions were prepared and transferred into a dialysis membrane tubing 
(Thermo, Slide-ALyzer MINI Dialysis Devices, 10K MWCO). The tubing was 
immersed in 10 mL of the PBS buffer (pH 5.6 and 7.4), placed in an incubator at 37 °C 
and stirred at 100 rpm. At specific time intervals, 0.5 mL samples were removed from 
the release medium and replaced with the same volume of fresh buffer. A calibration 
curve was established with a known concentration of free DOX by fluorescence emission 
measurements at 595 nm using NanoDrop3300. The amount of released DOX was 
Aptamer mediated niosomal drug delivery 
60 
 
calculated according to the calibration curve (y=254.93x-30.74, R2 = 0.9960, LOD=0.61 
µg/mL, LOQ= 1.84 µg/mL). 
 
Cell culture 
HeLa and U87 cell lines were provided from German Collection of Microorganisms and 
Cell Cultures (DSMZ). Both cell lines were grown in DMEM containing 10% fetal calf 
serum (FCS) and 1.0% penicillin/streptomycin (P/S). All cells were cultivated in medium 
and incubated with samples and reagents at 37°C in a humidified environment with 5.0% 
CO2. 
 
MUC1 expression on cell surfaces 
PCR and flow cytometry analysis were used to confirm expression of the MUC1 receptor 
in HeLa and lack of expression in U87 cells. Total cellular RNA of the cells was isolated 
using Trizol reagent (Invitrogen) and transcribed into cDNA. The primers were designed 
with Lasergene Primer Select Soft ware using the NCBI reference mRNA sequence for 
Homosapiens mucin 1, cell surface associated (MUC1), transcript variant 1 (NM-
002456.5). The primer sequences are as follows: MUC1 forward 5´-TAC CGA TCG 
TAG CCC CTA TG-3´ and reverse 5´-CCA CAT GAG CTT CCA CAC AC-3´. The 
human housekeeping gene hypoxanthine phosphoribosyltransferase (HPRT) was 
additionally used to prove the successful synthesis of cDNA. The primer sequences are: 
HPRT forward 5´-AAG CTT GCT GGT GAA AAG GA-3´ and reverse 5´-AAG CAG 
ATG GCC ACA GAA CT-3´. The protocol described in our previous publication was 
used in the polymerase chain reactions.35 The annealing temperature of 60 °C was used 
for MUC1 and HPRT during PCR experiments. PCR products were separated in 1.5% 
agarose gel in TAE buffer and stained with 5.0 µL/100 mL buffer Roti-Safe Gel Stain 
ready to use by Thermo. The gel was run using the Thermo EC electrophoresis unit at 
100 V for 60 min and documented using an INTAS UV documentation system. For flow 
cytometry studies, 5×105cells were collected. 100 µL of 5.0 µM Cy5 labelled MUC1 
aptamer in PBS were added to the cells and the cell suspension was shaken at room 
temperature for 1 h with 500 rpm in the dark. The cells were washed once in 300 μL of 
PBS to remove unbound aptamer. Before flow cytometric analysis, cells were 
resuspended in 500 μL of PBS and the stained cells were analyzed in a BD Accuri C6 
flow cytometer. At least 20 000 gated events were observed in total and living cells were 
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gated in a dot plot of forward versus side scatter signals. For drawing dot plots and 
histograms the BD Accuri C6 software was used. 
 
Cytotoxicity 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assays were used 
to determine cytotoxicity of the niosomal formulations. Cells (8×103) were seeded out in 
96-well tissue plates (Sarstedt, USA) in a volume of 200 µL and cultivated for three days. 
After this cultivation time cells were washed once in PBS and treated with SUVs 
(PEGNIO, PEGNIO/DOX, PEGNIO/DOX/CysTAT-MUC1) and free DOX for 24 h and 
48 h. The equivalent concentration of free DOX was used in niosomal formulations.Then 
the samples were removed and cells were incubated in 110 µL/well 10% MTT solution 
(5.0 mg/mL in PBS) in medium for 4 h. During this incubation time, formazan complex 
was produced by the cells. 100 µL SDS solution (1.0 g SDS in 10 ml 0.01 M HCl) was 
added to each well to release the purple colored salt from the cells. After 24 h of 
incubation, UV–vis absorption was measured at 570 nm to 630 nm as the reference 
wavelength using a microplate reader Epoch Biotek. 
 
Cellular uptake and internalization 
The DOX uptake by HeLa and U87 cells for different DOX formulations was analyzed 
by flow cytometry. HeLa and U87 cells were treated with PEGNIO/DOX, 
PEGNIO/DOX/CysTAT-MUC1 and free DOX  for 2 h and treated cells were washed 
two times with PBS, and then analyzed in a BD Accuri C6 flow cytometer.  
Cellular internalization of PEGNIO/DOX/CysTAT-MUC1 was determined via 
fluorescence microscopy studies. HeLa and U87 cells were cultivated for 2 days on the 
chamber slides (µ slides 8 well purchased at ibidi GmbH) in a volume of 200 μL of the 
medium. PEGNIO/DOX/CysTAT-MUC1 was diluted with medium and then added to 
the cells. The cells were incubated for 4 h at 37°C and washed once in PBS. Afterward 
100 µL DAPI solution (1.0 µg/mL) was added to the cells and incubated for 15 min. 
After DAPI staining, the cells were washed with PBS once. Images were taken using an 
OLYMPUS BX41 fluorescence microscope equipped with an OLYMPUS SC30 camera. 
 
Statistical analysis 
Statistical analysis was performed using the GraphPad InStat statistical software. All 
experiments were repeated three times. The paired t-test was performed. The difference 
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between two groups was considered to be significant when the P value was less than 
0.05. 
 
4.1.5 Results  
Doxorubicin is one of the most extensively used broad-spectrum anticancer drugs. It 
accumulates inside the cell nucleus where it intercalates into DNA and inhibits the 
progression of topoisomerase II to cause DNA damage and cleavage.36,37 Long treatment 
durations and toxic side effects are inconvenient in the use of conventional 
chemotherapeutics.38 Recent studies show that, biocompatible nanoparticles, with an 
increased surface area to volume ratio can overcome non-cellular and cellular-based 
mechanisms of resistance and increase the selectivity of drugs towards cancer cells, while 
reducing their toxicity towards normal tissues.39 The addition of PEG to the nanoparticle 
surface prolongs vesicles residence time in blood and accumulation at the pathological 
sites.5 Taking this into consideration, we decided to use PEGylated niosomes for 
obtaining aptamer targeted-cell penetrating vesicular systems. 
 
Conjugation and characterization of CysTAT–MUC1 
BS3 is an amine reactive, homobifunctional, sulfo-NHS ester, crosslinking reagent.40 
The reactivity of the sulfo-NHS esters is highly reactive toward amines in the pH range 
of 7–9. The amine modified MUC1 aptamer was reacted with the –NH2 group in the 
CysTAT peptide in the presence of BS3 to produce the CysTAT–MUC1 conjugates. 
Besides the desired conjugate CysTAT–MUC1, the reaction can also result in dimers of 
MUC1 aptamer and peptide. In order to investigate the product spectrum of the 
crosslinking reaction, gel electrophoresis was performed. Free MUC1 aptamer and 
CysTAT–MUC1 were applied to Urea PAGE. A single band was observed for free 
aptamer. In the case of CysTAT–MUC1 conjugate double bands were observed (Fig. 
S4.1). In the double bands, first band indicates CysTAT–MUC1 conjugate and the 
second one exhibits unbound aptamers in the conjugate. Additionally, the conjugation of 
aptamer and peptide was proven by HPLC analysis. For this aim, chromatograms of 
MUC1 aptamer, BS3 crosslinker, Cys-TAT peptide were compared with chromatogram 
of CysTAT–MUC1 conjugate (Fig. S4.2). No peaks were observed for MUC1 aptamer 
in this HPLC method. CysTAT peptide and BS3 crosslinker have different retention 
times 7.75 and 8.67 respectively, showed that there is no interference during the analysis 
of the CysTAT–MUC1 conjugates. The conjugation efficiency was about 82% in 
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accordance with the integrated areas of CysTAT peptide before and after conjugation. 
Besides CysTAT–MUC1, the conjugation can also result in aptamer and peptide dimers. 
Nonetheless, since these side products are not able to bind to maleimide group of 
PEGNIO (due to the lack of –SH group), we used to the as prepared conjugate with no 
additional purification.  
 
Synthesis and characterizations of DOX loaded niosomal formulations 
PEGylated niosomes were prepared by the thin film layer hydration technique, using 
span60:cholesterol:DSPE-PEG(2000)Maleimide. 0.22 mM doxorubicin solutions were 
used in the preparation of loaded vesicles. CysTAT–MUC1 was conjugated to 
PEGNIO/DOX to obtain targeted drug delivery system. The size of nanocarriers is very 
important for effective accumulation in tumor by enhanced permeability and retention 
effect (EPR) and cellular internalization. The mean diameters of empty and doxorubicin-
loaded niosomal formulations, along with the corresponding polydispersity index (PDI), 
doxorubicin entrapment efficiency (E%) values, and zeta potential values are listed in 
Table 4.1. The empty vesicle size was analyzed to be 151.0 ± 36nm. The hydrodynamic 
diameter did not change after DOX loading (152.7 ±34 nm) but after conjugation with 
CysTAT–MUC1 it increased to 164.5±40 nm. The stealth niosomes showed zeta 
potential values close to 0 mV but the surfaces of nanoparticles was grafted with PEG to 
improve water solubility and avoid aggregation.5,41,42 Due to the presence of PEG in the 
niosome structure, no aggregation was observed. DOX loading influenced the zeta 
potential of the vesicles. The change in the zeta potential may be a result of DOX 
intercalation in the vesicle membrane.5,43,44 Conjugation of CysTAT–MUC1 increased 
niosome size, corresponding with the presence of the aptamer on the niosomal surface 
increasing the hydrodynamic diameter. Moreover, the negatively charged DNA aptamer 
reduced the surface potential of the niosome.29 PDI ranged from 0.275 to 0.214, 
demonstrating that the vesicle population is relatively homogeneous in size. The DOX 
entrapment efficacy (E%) was calculated to be around 39% and 37% for PEGNIO/DOX 
and PEGNIO/DOX/CysTAT–MUC1 respectively. The stability of niosomal DOX 
formulations was tested via DLS analysis and no changes were observed in the size and 
PDI values after two months storage at 4 °C in the dark (data not shown). Additionally, 
PEGNIO/DOX/CysTAT–MUC1 sample was diluted in cell culture media and was 
incubated at 37 °C for 24 hours. The size of the sample was measured before and after 
incubation and no changes were observed. 
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Table 4.1 Characterization of PEGNIO formulations incorporating DOX 
 
Drug release 
Sustained drug release is one of the important properties of nanoscale drug delivery 
systems that will minimize side effects of the drug. In vesicular drug carrier systems, the 
drug release occurs by passive transport of the drug through the membrane bilayer.45 The 
release of DOX from PEGNIO/DOX/CysTAT–MUC1 was investigated using dialysis 
methods at pH 7.4, which was chosen in accordance with physiological conditions and 
in an acidic environment (pH 5.6). The solutions were taken out at specific intervals and 
measured by fluorescence emission measurements at 595 nm to determine the amount of 
DOX that has been released. The in vitro DOX release profiles from 
PEGNIO/DOX/CysTAT–MUC1 showed the faster release of DOX under acidic 
environments than that at neutral pH (Fig. 4.1). Within 48 h, the release of DOX was 
30% and 52% at pH 7.4 and pH 5.6 respectively. This can be explained by the higher 
solubility of DOX at the lower pH.46 Especially, the pH change from 7.4 to 5.6 
corresponds to the pH change from the normal physiological environment in body 
circulation to the intracellular tumor tissue. According to results, this conjugate is 
expected to be a promising drug delivery system for the tumor targeted delivery of DOX. 
 
 
 
Samples Size (nm) 
Intensity (%) 
(Mean±SD) 
Poly-
dispersity 
Index 
(PDI) 
Zeta Potential 
(mV) 
Entrapment 
Efficiency 
E% 
PEGNIO 151.0 ± 36             0.244  -4.96 ± 0.43 - 
PEGNIO/DOX 152.7 ± 34 0.214 -3.56 ± 0.27 39.52 ±1.8 
PEGNIO/DOX/        
CysTAT-MUC1        
164.5 ± 40 0.275 -8.62 ± 0.50 37.48 ±2.1 
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Figure 4.1 In vitro cumulative release of DOX from PEGNIO/DOX/CysTAT-MUC1 at pH 7.4 
and 5.6. 
 
Confirmation of MUC1 receptor expression on the cell surface 
To test PEGNIO/DOX/CysTAT–MUC1 as a targeted drug delivery system in vitro, first 
the expression of MUC1 was evaluated in HeLa and U87 cells. Gene expression of 
MUC1 was investigated at the mRNA level using polymerase chain reaction (PCR) and 
at the cell surface protein level using flow cytometry. Agarose gel analysis with the 
results of PCR experiments is shown in Fig. 4.2. The housekeeping gene (HPRT) was 
measured as a control for both HeLa and U87 cells (Fig. 4.2a and b). Bands 
corresponding to housekeeping genes were observed for both cell types (263 bp) 
confirming the success of RNA extraction and PCR. Fig. 4.2a demonstrates that HeLa 
cells show a high level of transcription of theMUC1 gene, which results in a strong band 
at the expected base pair length of 283 bp. No corresponding band was observed in U87 
cells, thereby indicating the lack of expression of MUC1. The PCR results were also 
confirmed by using Cy5 labeled MUC1 aptamer in flow cytometry. Cells were treated 
with a Cy5 labeled MUC1 aptamer. After the treatment, the mean fluorescence intensity 
was measured to be 28 523 for U87 cells, and 57 993 for HeLa cells (Fig. 4.2c). Both 
methods confirmed that MUC1 expression was considerably higher in HeLa cells than 
in U87 cells. These results are in agreement with the literature.47,48 
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Figure 4.2 Image of 1.5% agarose gel with results of PCR for HPRT gene and MUC1 expression 
in HeLa and U87 cells (a, b). Flow cytometry analysis of MUC1 expression on HeLa and U87 
cells using Cy5-labelled aptamer S2.2 (c). 
 
Cellular uptake and internalization 
Flow cytometry was used to investigate the total DOX uptake by HeLa and U87 cells for 
different DOX formulations and to evaluate receptor mediated cell targeting. The cells 
were treated with samples for 2 h. Untreated control cells and treated cells were analyzed 
using a BD Accuri C6 flow cytometer. As shown in Fig. 4.3a, the cellular DOX level for 
PEGNIO/DOX/CysTAT–MUC1 in HeLa cells was higher than that of PEGNIO/DOX 
and free DOX. Free DOX enters the cells by diffusion, leading to higher drug levels than 
found with the PEGNIO/DOX. After encapsulation of DOX in PEGNIO, the DOX 
uptake by diffusion is reduced.49 In the case of U87 cells, the uptake of free DOX was 
higher than PEGNIO/DOX/CysTAT–MUC1 (Fig. 4.3b). Fig. 4.3c indicates that the 
synthesized PEGNIO/DOX/CysTAT–MUC1 conjugate bound to MUC1 positive HeLa 
cell specifically. Nonspecific binding to U87 cells was also observed, but the 
fluorescence signals were lower than for HeLa cells. Cellular internalization of 
PEGNIO/DOX/CysTAT–MUC1 obtained by fluorescence microscopy analysis. DOX is 
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a fluorescent drug and, it localizes to the nucleus in tumor cells.50 Both cell lines were 
treated with PEGNIO/DOX/CysTAT–MUC1 for 4 h. The synthesized conjugate bound 
to HeLa cells, resulting in high fluorescence of the cell nucleus, thereby demonstrating 
successful internalization. In contrast, fluorescence was 
significantly lower for U87 cells, indicating some nonspecific uptake in U87 cells (Fig. 
4.4a and b). Fluorescence microscopy images show results similar to flow cytometry 
analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Flow cytometric measurement of DOX uptake by Hela (a) and U87 cells (b) after 
incubating with PEGNIO/DOX, PEGNIO/DOX/CysTAT-MUC1 and free DOX. Histogram of 
binding of PEGNIO/DOX/CysTAT-MUC1 to MUC1 positive HeLa cells and MUC1 negative 
U87 cells (c). 
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Figure 4.4 Fluorescence microscopy images of HeLa (a) and U87 cells (b). 
PEGNIO/DOX/CysTAT-MUC1 was incubated with the cells for 4 h at 37 °C. 
 
Cytotoxicity 
The cytotoxicity of bare niosomes, drug loaded formulations and free DOX was 
investigated by MTT assay using HeLa and U87 cells. PEGNIO was practically nontoxic 
to HeLa and U87 cells with relative cell viabilities above 80% for both 24 and 
48 h (Fig. 4.5). PEGNIO/DOX was less toxic than free DOX on both cell lines after 24 
and 48 h. This can be explained by the reduced diffusive uptake of PEGNIO/DOX in 
comparison to free DOX (Fig. 4.3a and b).49,51 Due to the conjugation of the targeting 
ligand to PEGNIO/DOX, PEGNIO/DOX/CysTAT–MUC1 was more toxic to HeLa cells 
than to U87 cells after 24 and for 48 h. Both, after 24 and 48 hours PEGNIO/DOX/Cys-
TAT–MUC1 had less cytotoxic effect of on U87 cells in comparison with free DOX 
(p<0.01 and p<0.05 respectively). PEGNIO/DOX/CysTAT–MUC1 increased the 
cytotoxicity for HeLa cells in comparison to PEGNIO/DOX for 24 and 48 hours (p < 
0.01 and p < 0.05 respectively). Moreover, in comparison to free DOX, 
PEGNIO/DOX/CysTAT–MUC1 showed a significantly increased toxic effect on HeLa 
cells after 48 h. According to obtained results, it is clear that the aptamer conjugated 
niosomal formulation acted as a targeted DOX delivery platform for MUC1 expressing 
tumor cells. 
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Figure 4.5 Cytotoxicity of the free drug and niosomal formulations on HeLa and U87 cells. Cells 
were incubated with PEG/NIO, PEGNIO/DOX, PEGNIO/DOX/CysTAT-MUC1 and free DOX 
(equivalent concentration of loaded DOX) for 24 h (a) and for 48 h (b). MTT assay was applied. 
Error bars represent the standard deviation from the mean (N=3). Data were analyzed using 
paired t-test, and *p < 0.05, **p < 0.01 was considered significant and very significant 
respectively. 
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4.1.6 Conclusions 
The objective of this study was to develop an efficient aptamer targeted niosomal drug 
delivery system. For this aim, PEGNIO was successfully synthesized by the thin film 
hydration method. The model drug DOX was encapsulated into the vesicles, and the 
surface of the vesicles was decorated with cell penetrating peptides and MUC1 aptamer 
as a targeting ligand. The drug loaded niosomes exhibit great potential as targeting drug 
carriers. The targeted drug-loaded nanoparticles show stronger cytotoxicity of the MUC1 
receptor overexpressed HeLa cells. As a conclusion, the formulation 
PEGNIO/DOX/CysTAT–MUC1 might be a promising and efficient strategy for the 
delivery of DOX to MUC1 overexpressed tumor cells. 
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4.1.8 Supplementary information 
  
 
 
 
 
Figure S4.1 Confirmation of conjugation of MUC1 aptamer with CysTAT peptide (Urea PAGE) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S4.2 HPLC chromatogram of MUC1 aptamer, BS3 crosslinker, CysTAT peptide and 
CysTAT-MUC1 conjugate. 
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4.2 Tumor homing and penetrating peptide conjugated niosomes as multi-
drug carriers for tumor-targeted drug delivery 
This chapter was published as D. Ag Seleci, M .Seleci, F. Stahl, and T. Scheper, Tumor 
homing and penetrating peptide conjugated niosomes as multi-drug carriers for tumor-targeted 
drug delivery, RSC Advances, 2017, 7, 33378–33384. It was reproduced with permission 
of Royal Society of Chemistry.  
 
4.2.1 Summary 
Many types of cancer cannot be treated with only one type of drug due to the pathological 
complexity of tumor tissues. Using multiple drugs might result in synergistic or additive 
effects at a lower dose compared with mono-chemotherapy. Furthermore, the low dose 
combination therapy may reduce adverse effects. Therefore, the combination therapy is 
a promising approach in clinical chemotherapy. Development of novel delivery systems 
using several nanomaterials provides to deliver multiple drugs via incorporation in one 
single carrier. Niosomes are one of the drug carriers exhibiting a bilayer structure and 
can accommodate hydrophilic drugs in their core and lipophilic drugs in their membrane 
at the same time. Here, polyethylene glycol modified niosomes (PEGNIO) were prepared 
from span60, cholesterol and 1,2-distearoyl-snglycero-3-phosphoethanolamine-N-
[maleimide (polyethyleneglycol)-2000] (DSPE-PEG (2000) Maleimide) via thin film 
hydration method. Curcumin (C) and doxorubicin (D) were encapsulated into the 
PEGNIO. The tumor-homing peptide tLyp-1, which has high affinity and specificity to 
neuropilin receptor (NRP-1), was conjugated to C and D loaded PEGNIO (PEGNIO/D–
C) via the formation of a thioether linkage. Detailed characterization studies were 
performed. The morphology of large unilamellar PEGNIO was monitored via upright 
microscopy and results showed that PEGNIOs were spherical and homogeneous in 
shape. The size of bare niosomes was analyzed to be 150 nm using Dynamic Light 
Scattering (DLS). After co-encapsulation of doxorubicin and curcumin, a slightly smaller 
hydrodynamic diameter as 144 nm was obtained. The conjugation of tLyp-1 did not 
affect the size of the niosomes significantly. The size was measured to be 146 nm for 
PEGNIO/D–C/tLyp-1. The stability of PEGNIO/D–C/tLyp-1 was tested via measuring 
the size and no changes were observed in the size after 30 days storage at 4 °C in the 
dark. Moreover, the entrapment efficacy (E%) was calculated to be 32.6 ±1.9% for 
curcumin and 23.3 ± 1.6% for doxorubicin. The t-Lyp-1 peptide conjugation efficiency 
was calculated to be 23.9% using BCA Assay. Dialysis method was used to study the 
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release of doxorubicin and curcumin from PEGNIO/D–C/t-Lyp-1.Two different pH 
values were used for release. Here pH 7.4 and pH 5.6 were chosen to mimic physiological 
conditions and acidic tumor environment respectively. The release profiles of 
doxorubicin and curcumin from PEGNIO/D–C/t-Lyp-1 showed faster release of both 
drugs under acidic environments. To test the specificity of t-Lyp-1 targeted niosomes, 
Rh6g was used as a model fluorescent dye and encapsulated into niosomes. The uptake 
of the Rh6g loaded niosomal formulations by glioblastoma cells (U87, NRP-1 positive) 
and human mesenchymal stem cells (hMSC, NRP-1 negative) cells were analyzed by 
flow cytometry. Results showed that PEGNIO/Rh6g/tLyp-1 was taken up by U87 cells 
specifically. The cytotoxic effects of niosomal formulations on U87 and hMSC cells 
were tested via MTT assays. PEGNIO/D–C/t-Lyp-1 was significantly more cytotoxic for 
U87 cells in comparison to free D–C. Besides, PEGNIO/D–C/t-Lyp-1 was more toxic to 
U87 cells than to hMSC cells. Furthermore, the effect of free D–C, PEGNIO/D–C and 
PEGNIO/D–C/tLyp-1 on tumor-like spheroids formed by U87 cells, was evaluated for 6 
days. The morphological changes of treated versus non-treated spheroids were monitored 
via bright field microscopy. PEGNIO/D–C/tLyp-1 treated spheroids became distorted, 
with many disassociated cells. According to all obtained results, it can be concluded that 
this targeted and codrug-loaded niosomal delivery system could improve the efficacy of 
doxorubicin on glioma therapy.  
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4.2.2 Abstract 
Development of nanoscale drug delivery systems, which can mediate efficient tumor 
targeting together with high cellular internalization, is crucial for glioma treatment. 
Combination of therapeutic agents in nanoparticles provides synergistic effects and 
allows further surface modifications with targeting ligands for specific glioma therapy. 
To achieve this goal, both doxorubicin and curcumin were encapsulated in polyethlene 
glycolated niosomes (PEGNIO). The surface of co-drug loaded PEGNIO was modified 
with tumor homing and penetrating peptide (tLyp-1). Physicochemical properties were 
determined via dynamic light scattering (DLS) and spectral analysis. Moreover, flow 
cytometry studies were performed to examine the specific cellular uptake of the tLyp-1 
targeted niosomal formulation. In vitro cytotoxicity and inhibition of tumor-like 
spheroids growth were investigated on human glioblastoma (U87) and human 
mesenchymal stem cells (hMSC) cells. The results clearly indicated that the strategy by 
co-administration of doxorubicin and curcumin with tLyp-1 functionalized niosomes 
could significantly improve anti-glioma treatment. 
 
4.2.3 Introduction  
Glioblastoma is a malignant brain tumor and patients diagnosed with glioma have a 
median survival of less than 2 years. The current treatment for brain cancer is usually 
chemotherapy. However, the therapeutic efficacy of many anticancer drugs is limited by 
the existence of the blood-brain barrier (BBB), the blood-brain tumor barrier (BBTB), a 
relatively weak enhanced permeability and retention (EPR) effect and by their severe 
side effects on healthy cells.1  
Combination of therapeutic agents has recently attracted great attention for glioblastoma 
chemotherapy.2 It provides synergistic effects and decrease adverse side effects 
associated with high doses of single anticancer drugs and helps to avoid drug resistance.3 
Over the last decade, the advances in nanomedicine have enabled to develop novel 
nanocarriers for site-specific drug delivery and to gain access to brain tumors.4, 5 By 
taking advantages of these nanocarriers, different combinations of various drugs were 
co-loaded on nanoparticles for glioma therapy.6, 7 Dilnawaz et al. loaded both curcumin 
and temozolomide into magnetic nanoparticles (MNPs) and studied their in vitro 
cytotoxic effects on 3D glioma tumor spheroids. The dual drug loaded MNPs 
formulations demonstrated higher cytotoxic effects than the single drug loaded MNPs 
formulations as compared to their corresponding native drugs in 2D and 3D culture.6 In 
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another study Xu et al. studied in vitro cytotoxicity effects of paclitaxel and 
temozolomide co-loaded in polymer nanocomposites and the results suggested that the 
composite gel possessed much higher growth-inhibiting effects as well as apoptosis-
inducing rates in glioma cells than other formulations.8  
Niosomes are drug carriers exhibiting a bilayer structure and are in most cases formed 
by self-association of non-ionic surfactants and cholesterol in aqueous phase. They can 
accommodate a large number of drugs with a wide range of solubilities.9, 10 Hydrophilic 
drugs and lipophilic drugs can be entrapped into the aqueous core and membrane bilayer 
of niosome respectively.11, 12 Therefore, niosomes are promising nanocarriers in multi-
drug delivery applications. The efficiency of niosomal multi-drug delivery systems can 
be further improved by active targeting for tumor therapy by using a ligand coupled to 
the surface of niosomes. In this way, nanocarriers can be actively taken up, for example, 
via receptor-mediated endocytosis.13 Recently, Tavano et al. reported the dual 
encapsulation of hydrophobic curcumin or quercetin and hydrophilic doxorubicin in 
Pluronic-based niosomes for cancer multi-drug delivery.14 Besides, the surface of the 
niosomes was coupled with transferrin and/or folic acid for breast cancer targeting. 
Results showed the high potential of the dual drug loaded niosomes in breast tumor 
treatment.  
Neuropilin-1 (NRP-1) is a transmembrane protein overexpressed on the surface of both 
glioma and endothelial cells of angiogenic blood vessels.15-17 CGNKRTR (tLyP-1) is a 
homing peptide which penetrates tumor cell through an NRP-1 mediated endocytosis via 
C-end Rule (CendR) internalization pathway.18, 19 Therefore, tLyP-1 is a promising 
targeting ligand for the delivery of therapeutic agents to tumors. Xu et al. produced tLyp-
1 targeted camptothecin-loaded mesoporous silica nanoparticles and it showed minimal 
adverse effects on human mesenchymal stem cells (hMSC), whereas significant 
induction of tumor cell death was observed.20 Moreover, Hu et al. conjugated the tLyp-
1 peptide to the surface of paclitaxel (PTX) loaded PEG-PLA nanoparticles via a 
maleimide-thiol coupling reaction for anti-glioma drug delivery. They achieved the 
longest survival of the mice bearing intracranial C6 glioma treated with PTX-loaded 
tLyp-1-nanoparticles in comparison to PTX loaded nanoparticles.17  
In this study, polyethylene glycolated niosomes (PEGNIO) were prepared from span60, 
cholesterol and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide 
(polyethylene glycol)-2000] (DSPE-PEG (2000) Maleimide) for multi-drug delivery. 
Curcumin (C) and doxorubicin (D) were encapsulated into the PEGNIO. The tumor-
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homing peptide tLyp-1 was conjugated to C and D encapsulated PEGNIO (PEGNIO/D-
C) via the formation of a thioether linkage. The effect of the PEGNIO/D-C/tLyp-1 on 
human glioblastoma cells (U87) and hMSC was investigated in detail. Our results 
suggest that this targeted and co-loaded drug delivery platform could improve the 
efficacy of doxorubicin on glioma therapy. 
 
4.2.4 Materials and methods  
 
Materials  
DSPE-PEG(2000) Maleimide was provided by Avanti (Alabama, USA). Sorbitan 
monostearate (Span60), cholesterol, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazoliumbromide (MTT), Dulbecco’s Modified Eagle Medium (DMEM), curcumin 
and rhodamine 6G (Rh6g) were ordered from Sigma Aldrich (Munich, Germany). Alpha 
Minimum Essential Media (Alpha-MEM) was purchased from Life Technologies 
(Darmstadt, Germany). Doxorubicin hydrochloride was purchased from Cayman 
Chemical (Michigan, USA). tLyP-1 peptide (CGNKRTR) was ordered from GeneCust 
(Ellange, Luxembourg). 
 
Preparation of niosomes  
The thin film hydration method was used to prepare PEGylated niosomes.21 Span 60, 
cholesterol and DSPE-PEG(2000) Maleimide were dissolved in 1.0 mL chloroform in a 
round-bottom flask with the mM ratio (4.95:4.95:0.1). The solvent was evaporated with 
constant rotation under reduced pressure to form a thin lipid film. Doxorubicin or Rh6g 
loaded niosomes were obtained by hydrating the thin lipid film with 1.0 mL of 
doxorubicin or Rh6g (0.22 × 10-3 and 0.42 × 10-3 M, respectively) aqueous solution at 60 
°C for 60 min.14, 22 To obtain doxorubicin-curcumin-loaded niosomes, 200 μL of 
curcumin solution (2.18 × 10-3 M) was added to the initial chloroform mixture.14 After 
vortexing, the solvent was evaporated under reduced pressure, and the obtained film was 
then hydrated with 1.0 mL of doxorubicin aqueous solution at 60 °C for 60 min. 
Afterward, the niosomal solution was equilibrated at room temperature overnight to 
complete annealing and partitioning of the drug between the lipid bilayer and the aqueous 
phase.23 Small unilamellar vesicles (SUVs) were prepared starting from multilamellar 
vesicles (MLVs) by sonication in an ultrasonic bath and following extruding the 
niosomes through 0.4 μm and 0.1 μm pore size polycarbonate filters (mini-extruder set 
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Avanti polar lipids, sample volume 1.0 mL). Niosomes were purified by a flow of 
niosome suspensions across a Sephadex G-25 gel column and volume of eluted niosomes 
was adjusted to 1.0 mL. 
 
Preparation and characterization of tLyp-1 conjugated niosomes  
For the preparation of tLyp-1 targeted niosomes, the thiol group of tLyp-1 was coupled 
with the maleimide group of PEG chains on niosomes. tLyp-1 peptide was dissolved in 
50 mM HEPES buffer, pH 6.5 at 200 μg mL-1 concentration (50 μL) were reacted with 
niosomes (950 μL) for overnight at room temperature resulting in the formation of a 
thioether linkage.24, 25 The products were then purified using a 14 kDa dialysis bag to 
remove the unconjugated peptides. Schematic representation of co-drug encapsulation 
and the bioconjugation processes are shown in Scheme 1.  
 
 
 
 
 
 
Scheme 1. Schematic representation of co-drug encapsulation and the bioconjugation process 
(yellow dots: curcumin, red dots: doxorubicin). 
 
The size of the niosomes were measured by dynamic light scattering (DLS) analysis 
using Malvern Zetasizer Nano ZSP. The polydispersity index (PDI) was used as a 
measure of the width of size distribution. Each sample was measured three times. The 
morphology of large unilamellar PEGNIO (before extrusion) was monitored via 
Olympus BX41 upright microscope. 100X immersion oil objective was used.  
To estimate the tLyp-1 conjugation efficiency, BCA Protein Assay was used.4 25 μL of 
BSA standards, PEGNIO (as blank) and PEGNIO/tLyp-1 were added in triplicate wells 
(96-well plate) and 200 μL of BCA Protein Assay Reagent were added to the samples. 
After incubation at 37 °C for 30 min, the absorption was measured via microplate reader 
(BioTek Epoch) at 562 nm. Conjugation efficiency was expressed as the percentage of 
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the peptide bound to the surface of noisome, referred to the amount of peptide that is 
present initially. 
 
Stability  
The stability of PEGNIO/D-C/tLyp-1 was tested via DLS analysis. PEGNIO/D-C/tLyp-
1 was stored at 4 °C in the dark. The particle size and PDI values were measured after 
30 days. Moreover, the particle size of PEGNIO/D-C/tLyp-1 was measured in cell culture 
media after the incubation at 37 °C for 24 h.  
 
Entrapment efficiency  
After encapsulation, the D-C loaded niosomes were purified using Sephadex G-25 gel 
column. The percent of encapsulation efficiency (E%) was expressed as the percentage 
of the drug entrapped in niosomes (and thus not removed via Sephadex column) referred 
to the initial amount of drug that is present in the non-purified sample  (Equation 1). 200 
μL of non-purified and purified niosomes diluted in 600 μL of methanol and niosomes 
were separated by centrifugation at 12,000 rpm for 5 min. This step allows the breaking 
of niosomal membranes and the release of the encapsulated drug. A calibration curve 
was derived with a known concentration of free doxorubicin by fluorescence emission 
measurements at 595 nm using NanoDrop 3300. The stock solutions of doxorubicin were 
prepared at 1.0 mg mL-1 in methanol and further diluted with methanol in the 
concentration range 1.0–50 μg mL-1. The amount of doxorubicin in purified and non-
purified samples was calculated according to the calibration curve (y = 850.94x+12.092, 
R2 =0.9973) via measuring fluorescence emission at 595 nm. The limit of detection 
(LOD) and limit of quantification (LOQ) for doxorubicin were found to be 4.92 μg mL-
1
 and 14.92 μg mL-1 respectively, based on 3.3σ/slope and 10sσ/slope formulations. The 
amount of curcumin in purified and non-purified samples was calculated according to 
the calibration curve (y=0.1459x+0.0058, R2=1, LOD=0.15 μg mL-1 and LOQ=0.46 μg 
mL-1), which was established with a known concentration of free curcumin (0.5-10 μg 
mL-1) by absorbance measurements at 426 nm using a microplate reader (BioTek Epoch). 
 𝐄 (%) = 𝐀𝐦𝐨𝐮𝐧𝐭 𝐨𝐟 𝐝𝐫𝐮𝐠  𝐢𝐧 𝐩𝐮𝐫𝐢𝐟𝐢𝐞𝐝 𝐬𝐚𝐦𝐩𝐥𝐞  𝐀𝐦𝐨𝐮𝐧𝐭 𝐨𝐟 𝐝𝐫𝐮𝐠 𝐢𝐧 𝐧𝐨𝐧 − 𝐩𝐮𝐫𝐢𝐟𝐢𝐞𝐝 𝐬𝐚𝐦𝐩𝐥𝐞 × 𝟏𝟎𝟎 
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Drug release  
The in vitro release profiles of curcumin and doxorubicin from PEGNIO/D-C/tLyp-1 
were studied using a dialysis method. PEGNIO/D-C/tLyp-1 solutions were prepared and 
transferred into a dialysis membrane tubing (Thermo, Slide-ALyzer MINI Dialysis 
Devices, 10k MWCO). The tubing was immersed in 10 mL of the PBS buffer (pH 5.6 
and 7.4) containing Tween80 (1.0%, v/v), placed in an incubator at 37 °C and stirred at 
100 rpm. Here, Tween 80 was added to obtain optimal release conditions since curcumin 
has limited solubility in PBS.26 At predetermined time intervals, 0.5 mL samples were 
removed from the release medium and replaced with the same volume of fresh buffer. 
The amount of released doxorubicin and curcumin was calculated as % according to the 
calibration curves and in respect to loading concentration (the drug concentration in 
niosomes, before starting the release). They were established with a known concentration 
of free doxorubicin and free curcumin by fluorescence emission measurements at 595 
nm using NanoDrop 3300 and absorbance measurements at 426 nm using a microplate 
reader respectively. 
 
Cell culture  
U87 cell lines were provided from German Collection of Microorganisms and Cell 
Cultures (DSMZ).U87 cells were grown in DMEM containing 10% fetal calf serum 
(FCS) (Biochrom GmbH, Germany) and 1.0% penicillin/streptomycin (P/S). Human 
adipose-derived mesenchymal stem cells (hMSCs) were isolated from subcutaneous 
adipose tissues of 3 different patients scheduled for abdominoplasty after obtaining 
informed written consent, as approved by the Institutional Review Board, project #2251-
2014 on 15th May, 2014. The isolated populations have been extensively characterized 
as mesenchymal stem cells by surface marker analysis and functional properties 
(differentiation capacity). hMSCs were cultured in alpha-MEM including 10% human 
serum (HS) (HS, c.c.pro GmbH, Germany)and 0.5% gentamicin. Both cell lines were 
cultivated and incubated with samples at 37 °C in a humidified environment with 5.0% 
CO2.  
 
Cellular uptake  
Rh6g was used as a model fluorescent dye and encapsulated into niosomes. The uptake 
of the Rh6g loaded niosomal formulations by U87 and hMSC cells was analyzed by flow 
cytometry. The cells (4x104) were treated with PEGNIO/Rh6g and PEGNIO/Rh6g/tLyp-
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1 for 2 h and treated cells were washed two times with PBS, and then analyzed in a BD 
Accuri C6 cytometer.  
 
Cytotoxicity  
The cytotoxic effects of niosomal formulations and free drugs were tested on U87 and 
hMSC cells using MTT assay. Cells (8x103) were seeded out in 96-well tissue plates 
(Sarstedt, USA) in a volume of 200 μL and cultivated for three days. After this cultivation 
time, cells were washed once with PBS and treated with PEGNIO/D-C, PEGNIO/D-
C/tLyp-1 and free D-C for 24 h. The equivalent concentration of free doxorubicin and 
curcumin was used in niosomal formulations. Then the samples were removed and cells 
were incubated in 110 μL per well 10% MTT solution (5.0 mg mL-1 in PBS) in the 
medium for 4 h. During this incubation time, formazan complex was produced by the 
cells. 100 μL SDS solution (1.0 g SDS in 10 mL 0.01 M HCl) were added to each well 
to release the purple colored salt from the cells. After 24 h of incubation, UV-Vis 
absorption was measured at 570 nm to 630 nm as the reference wavelength using a 
microplate reader Epoch Biotek. Besides, IC50 values (the drug concentration required 
for 50% inhibition of cell viability) were calculated for U87 cells using the growth 
sigmoidal/dose response function of Origin software.  
 
Effect on tumor-like multicellular spheroids  
The effect of niosomal formulations was tested on 3D spheroid cultures. U87 cells 
(8x103/well) in 100 μL of culture medium were seeded into 96-well round-bottom ultra 
low attachment plates (Sarstedt, Germany) and incubated for 2 days to form spheroids. 
Afterward, 100 μL of each sample (D-C, PEGNIO/D-C, PEGNIO/D-C/tLyp-1) was 
added to the spheroids and incubated further for 2, 4 and 6 days. Bright-field images of 
U87 tumor-like spheroids treated with the samples were taken with Olympus IX50 
inverted light microscope equipped with an Olympus camera (SC30, Japan) by using 
cellSens Standard software (Olympus Co. Japan).  
 
Statistical analysis  
Statistical data analysis was performed using the Student's t-test. The difference between 
two groups was considered significant when the p value was less than 0.05.  
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4.2.5 Results and discussion  
 
Characterizations of niosomal formulations  
The morphology of large unilamellar PEGNIO was monitored using an upright 
microscope (Figure S4.3). Figure S4.3 indicated that PEGNIOs were spherical and 
homogeneous in shape. The mean diameters of empty and co-drug-loaded niosomal 
formulations, along with the corresponding polydispersity index (PDI) and drug 
entrapment efficiency (E%) values, are listed in Table 4.2. The empty vesicle size was 
analyzed to be 150.3 nm. When doxorubicin and curcumin were co-encapsulated, a 
slightly smaller hydrodynamic diameter as 144.1 nm was obtained. In our previous study, 
we demonstrated, that the encapsulation of doxorubicin in PEGNIO did not result in an 
alteration of niosomal size.22 However, when a hydrophobic drug is encapsulated in the 
colloidal system, they were claimed to lead to H bonding between their hydroxyl groups 
and niosomal matrices, resulting in an increase in the niosomal cohesion and then a 
decrease in the diameter.14 Here, the decrease in the size can be attributed to the 
entrapment of hydrophobic curcumin in the bilayer. After the conjugation of tLyp-1, the 
size of the niosomes did not change significantly. The size was measured to be 146.1 nm 
for PEGNIO/D-C/tLyp-1. PDI less than 0.3 corresponds to a homogeneous population 
for colloidal systems.27 PDI ranged from 0.175 to 0.140 for the niosomal formulations, 
demonstrating that the vesicle population is relatively homogeneous in size. The 
entrapment efficacy (E%) was calculated to be 32.6±1.9% for curcumin and 23.3±1.6% 
for doxorubicin.  
Under the determined experimental conditions, the t-Lyp-1 peptide conjugation 
efficiency was calculated to be 23.9%.  
The stability of PEGNIO/D-C/tLyp-1 was tested via DLS analysis and no changes were 
observed in the size and PDI values after 30 days storage at 4 °C in the dark (data not 
shown). Furthermore, PEGNIO/D-C/tLyp-1 was diluted in cell culture media and was 
incubated at 37 °C for 24 hours. The size of the sample was measured and after incubation 
and no changes were observed. 
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Table 4.2 Characterization of PEGNIO formulations 
 
Drug release  
Prolonged drug retention and sustained drug release are important properties for 
nanoscale drug delivery systems that will minimize side effects of the drug.22 The unique 
structure of niosomes allows to control the release of the encapsulated drug combinations 
to increase antitumor activity.14 The release of doxorubicin and curcumin from 
PEGNIO/D-C/t-Lyp-1 was investigated using dialysis methods at pH 7.4, which was 
chosen in accordance with physiological conditions and in an acidic environment (pH 
5.6) similar to the tumor. The release profiles of doxorubicin and curcumin from 
PEGNIO/D-C/t-Lyp-1 showed the faster release of both drugs under acidic environments 
than that at neutral pH (Fig. 4.6). Within 32 h, the release of doxorubicin and curcumin 
was 74±1.2% and 62±0.6% at pH 5.6 respectively. At physiological pH, the release of 
curcumin and doxorubicin was 36±1.7% and 68±2.9%. According to results, this 
conjugate is expected to be a promising co-drug delivery system for the tumor-targeted 
therapy. 
Samples Size (nm) 
Intensity (%) 
(Mean±SD) 
Poly-dispersity 
Index 
(PDI) 
Entrapment 
Efficiency 
E% 
PEGNIO 150.3 ± 51              0.175 - 
PEGNIO/D-C 144.1 ± 61 0.152 D:23.3±1.6 
C:32.6±1.9 
PEGNIO/D-C/tLyp-1  146.1 ± 69 0.140 D:22.0±1.5 
C:31.2±1.8 
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Figure 4.6 In vitro cumulative release of doxorubicin and curcumin from PEGNIO/D-C/t-Lyp-
1 at pH 7.4 and 5.6. 
 
Cellular uptake  
To test the specificity of t-Lyp-1 targeted niosomes, Rh6g was encapsulated in 
PEGylated niosomes and further t-Lyp-1 was conjugated to PEG chains on niosomes. 
Flow cytometry was used to investigate the Rh6g uptake by hMSC and U87 cells to 
evaluate receptor-mediated cell targeting. The cells were treated with PEGNIO/Rh6g for 
2 h. Untreated control cells and treated cells were analyzed using a BD Accuri C6 flow 
cytometer. No differences were observed between targeted and non-targeted niosomal 
formulations treated hMSC (Fig. 4.7a). In the case of U87 cells, the uptake of 
PEGNIO/Rh6g/tLyp-1 was higher than PEGNIO/Rh6g (Fig. 4.7b). Fig.4.7c indicates 
that PEGNIO/Rh6g/tLyp-1 was uptaken by U87 cells specifically. tLyP-1 is able to 
selectively home in and penetrate into tumor cells mediated NRP-1 receptor which is 
overexpressed in tumor cells.20, 28 The expression of NRP-1 receptor, on the surface of 
the U87 cells would affect the enhanced cellular uptake of PEGNIO/Rh6g/tLyp-1. 
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Figure 4.7 Flow cytometry measurements of Rh6g uptake by hMSC (a) and U87 cells (b) after 
incubating with PEGNIO/Rh6g and PEGNIO/Rh6g/t-Lyp-1. Histogram of binding of 
PEGNIO/Rh6g/t-Lyp-1 to hMSC and U87 cells (c). 
 
Cytotoxicity  
Doxorubicin is classified as a topoisomerase-2 inhibitor and one of the most extensively 
used broad-spectrum anticancer drugs. However, it has some limitations in clinical use. 
Long treatment durations cause the development of resistance by tumor cells and toxicity 
for healthy tissues. Therefore, combinations of two or more agents have been used to 
overcome toxicity and other side effects of doxorubicin.29, 30 Curcumin’s therapeutic 
characteristics have been demonstrated against a wide range of cancers.31-33 The major 
drawback of curcumin is its poor solubility and stability in water. Thus, here doxorubicin 
and curcumin were encapsulated in PEGNIO and further the surface of niosome was 
modified with t-Lyp-1 peptide.  
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After confirming the NRP-1 receptor-mediated glioma cell binding efficiencies of the 
PEGNIO/Rh6g/tLyp-1 via flow cytometry, MTT assays were performed to evaluate 
relative abilities of the various niosomal formulations in inhibiting growth of tumor 
(U87) and non-cancer (hMSC) cells. PEGNIO/D-C was more toxic than free D-C on 
both cell lines (Fig. 4.8). Due to the conjugation of the targeting ligand to PEGNIO/D-
C, PEGNIO/D-C/t-Lyp-1 was more toxic to U87 cells than to hMSC cells after 24h 
(p<0.05). PEGNIO/D-C/t-Lyp-1 significantly increased the cytotoxicity for U87 cells in 
comparison to free D-C (p< 0.05). Moreover, U87 cells were treated with samples (D-C, 
PEGNIO/D-C and PEGNIO/D-C/t-Lyp-1 ) for 48 h at concentration range of 
doxorubicin (0-50 μg/mL). IC50 values were calculated as to be 0.96 μg/mL, 0.9 μg/mL 
and 0.76 μg/mL for D-C, PEGNIO/D-C and PEGNIO/D-C/t-Lyp-1 respectively. 
 
 
Figure 4.8 Cytotoxicity of the free drug and niosomal formulations on hMSC and U87 cells. 
Cells were incubated with, PEGNIO/D-C, PEGNIO/D-C/t-Lyp-1 and free D-C (equivalent 
concentration of loaded D-C) for 24 h. MTT assay was applied. Error bars represent the standard 
deviation from the mean (N=3). Data were analyzed using t-test, and *p < 0.05, **p < 0.01 was 
considered significant and very significant respectively. 
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Effect on tumor-like multicellular spheroids  
According to results obtained in 2D cell cultures, it is clear that the tLyp-1 conjugated 
niosomal formulation acted as a targeted multi-drug delivery platform for NRP-1 
expressing tumor cells. Further, we have used 3D spheroid model which is found to be 
relevant for therapeutic evaluation, as it reflects better the in vivo conditions both in 
structural and molecular aspects.34 The effect on tumor-like spheroids was evaluated 
following the treatment with cell culture media, free D-C, PEGNIO/D-C and 
PEGNIO/D-C/tLyp-1 for 6 days. As shown in Fig. 4.9a, the tumor spheroids treated with 
cell culture media retained their morphology (compact spheroids with smooth surface) 
over entire period of cultivation. The spheroids treated with D-C became smaller in 
diameter (Fig. 4.9b). The tumor spheroids exposed to niosomal formulations exhibited 
no more tightly organised structure (Fig. 4.9c, d). Especially, PEGNIO/D-C/tLyp-1 
treated spheroids became distorted, with many disassociated cells (Fig. 4.9d). These 
results demonstrated enhanced effects of PEGNIO/D-C/tLyp-1 on 3D tumor-like tissues 
in comparison to other formulations. 
 
Figure 4.9 Morphology of U87 tumor spheroids treated with cell culture media (a), D-C (b), 
PEGNIO/D-C (c) and PEGNIO/D-C/t-Lyp-1 (d) on days 0, 2, 4 and 6, respectively. 
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4.2.6 Conclusion  
In this work, a targeted niosomal co-drug delivery system was developed to improve the 
therapeutic efficacy of anti-glioma drug delivery. Curcumin and doxorubicin were 
encapsulated into PEGNIO by the thin film hydration method. The surface of PEGNIO 
was decorated with tLyp-1, which is tumor homing and penetrating peptide. Tumor-like 
structure dissociation in 3D tumor spheroids, enhanced cellular interaction, and increased 
cytotoxicity of the drugs in U87 cells were achieved by PEGNIO/D-C/tLyp-1. These data 
indicated that the formulation PEGNIO/D-C/tLyp-1 might be a promising and efficient 
strategy for drug delivery in anti-glioma therapy. 
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Figure S4.3 Optical micrographs of PEGNIO. Scale bar 10 µm. 
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5. Conclusions and Outlook 
The development of new nanocarriers offers great hope to overcome the limitations in 
traditional cancer therapy. Non-ionic surfactant based vesicles, termed niosomes, are 
increasingly remarked nanostructures used in drug delivery studies. Their synthesizing 
process is considerably cheap and simple. Due to their high stability, controlled release 
of the loaded agent can be enabled. The main components of the niosomes, surfactants, 
and lipid molecules are biodegradable and non-immunogenic. The therapeutic efficacy 
of the therapeutic molecules can be improved by reducing clearance rate, protecting the 
encapsulated molecule against environmental conditions, and targeting to the specific 
side of the body. Besides, the surface of niosomes can be coated and functionalized by 
using the hydrophilic molecules such as polyethylene glycol (PEG). Thus, clearance rate 
may be reduced and targeting molecules can be conjugated to achieve targeted delivery 
of loaded agents to the specific side of the body. Aptamers and peptides are some of the 
most utilized targeting moieties. In the presented studies, these ligands were combined 
with PEGylated niosomes and their characterizations as well as in vitro studies were 
carried out in detail. To the best of our knowledge, this is the first time that aptamer and 
peptides were combined and used as a targeting ligand in niosomal drug delivery 
systems. 
In the first study, the development of a niosomal drug delivery system with tumor 
targeting and penetrating features was aimed. Span60 and cholesterol were used to 
synthesize PEGylated niosomes via thin-film hydration method. The model drug 
doxorubicin (DOX) was encapsulated into the niosomes during hydration. On the other 
hand, a cell penetrating peptide, Cys-TAT and MUC1 aptamer, which can specifically 
bind to MUC1 glycoprotein expressed on tumor cell surface, were conjugated to each 
other by using BS3 homo-functional crosslinker. The conjugation was confirmed via gel 
electrophoresis and HPLC. Then, PEGylated niosome surface was modified with 
CysTAT–MUC1 targeting moiety through cysteine residue available in peptide 
sequence. The hydrodynamic size of the targeted drug loaded niosomes was determined 
around 165 nm with ~0.2 polydispersity index, which indicates homogeneity in the 
particle size. Drug release profiles were recorded at neutral and mild acidic conditions, 
7.4 and 5.6 respectively. Faster release of DOX from niosomes was observed under 
acidic pH. HeLa (cervical cancer) and U87 (human glioblastoma) cells were selected as 
the cell lines according to MUC1 protein expression levels by polymerase chain reaction 
(PCR) and flow cytometry. DOX uptake by HeLa and U87 cells were investigated for 
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different DOX formulations through flow cytometry. Targeted niosomes showed higher 
DOX level than nontargeted niosomes and free DOX in MUC1 positive HeLa cells. In 
contrary, the niosomal formulations, as well as free DOX showed almost the same 
cellular uptake on MUC1 negative U87 cell line. Fluorescence microscopy images 
correlate with the flow cytometric results. The cytotoxicity of the niosomal formulations 
and free DOX were examined with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazoliumbromide (MTT) assay on both cell lines for both 24 and 48 h. Plain niosomes 
indicated almost no toxic effect on both cell lines for all time points. 
PEGNIO/DOX/CysTAT–MUC1 revealed higher cytotoxicity on HeLa than U87 cells 
after 24 and 48 h because of the existence of the targeting ligand.      
In the second study, the design of targeted niosomal co-drug delivery system for the 
glioblastoma treatment was aimed. In recent years, the co-delivery of therapeutic agents 
has attracted great attention for glioblastoma chemotherapy. Especially the combination 
of curcumin and chemotherapeutics is a promising approach. Here curcumin and DOX 
were encapsulated in PEGNIO during its synthesis via thin film hydration method. Free 
drugs were removed by using a Sephadex G-25 gel column. Subsequently, the tumor-
homing peptide tLyp-1, which binds to U87 cells specifically, was conjugated to 
curcumin and DOX encapsulated PEGNIO (PEGNIO/D–C) via the formation of a 
thioether linkage. All niosomal formulations were characterized in detail. The 
hydrodynamic size, shape, entrapment efficiencies, and in vitro drug release profiles 
were evaluated. PEGNIO is round in shape and around 150 nm in size. Both drugs were 
released from niosomes faster under acidic pH. Moreover, to test the specificity of 
targeted niosomes, rhodamine 6g (Rh6g) was entrapped into the niosomes and t-Lyp-1 
was conjugated to PEG chains on niosomes. Flow cytometry was used to investigate the 
Rh6g uptake by hMSC (human mesenchymal stem cells) and U87 cells to evaluate 
receptor-mediated cell targeting. The specific uptake of peptide targeted niosomes by 
U87 cells was obtained. The cytotoxicity of the niosomal formulations and mixture of 
free drugs were examined via MTT assay on both cell lines for 24 h. tLyp-1 targeted co-
drug loaded niosomes showed higher cytotoxicity on U87 than on hMSC cells after 24 
h. Furthermore, tumor spheroids formed by U87 cells were treated with niosomal 
formulations. Spheroids exhibited the structure that there is no more tightly organized. 
Especially, PEGNIO/D–C/tLyp-1 treated spheroids became distorted, with many 
disassociated cells.  
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In conclusion, the fundamental information about niosomes, detailed information about 
their applications in drug delivery were provided in the theoretical part of this thesis. In 
the experimental part, two novel different targeted niosomal drug delivery systems for 
cancer therapy were designed, synthesized, characterized, and applied in vitro. Obtained 
results indicated that PEGNIO is a promising drug carrier for drug delivery studies, 
which enables the entrapment of different drugs and the conjugation of targeting ligands 
on its surface. However, in vivo applications have to be performed to further evaluate its 
potential as a commercial product. Currently, there is no commercial niosomal drug 
available. Therefore, further research studies need to be carried out in this field. The 
outcomes of this thesis may provide new insights and contribute the development of 
novel drug delivery devices for cancer therapy.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
List of Publications 
95 
 
List of Publications 
 
1. D. Ag Seleci (90%), M. Seleci (5%), R. Jonzcyk (5%), F. Stahl, and T. Scheper, 
Niosomes for Brain Targeting, Carriers for Brain Targeting, Apple Academic Press, 
submitted 30 June 2017 
2. D. Ag Seleci (95%), M. Seleci (5%), F. Stahl, and T. Scheper, Tumor homing and 
penetrating peptide-conjugated niosomes as multidrug carriers for tumor-targeted drug 
delivery, RSC Advances, 2017,7, 33378-33384.   
3. D. Ag Seleci (85 %), M. Seleci (10%), A. Jochums (5%), J.G. Walter, F. Stahl, and 
T. Scheper Aptamer mediated niosomal drug delivery, RCS Advances, 2016, 6, 87910–
87918.  
4. D. Ag Seleci (95%), M. Seleci (5%), J.G. Walter, F. Stahl, and T. Scheper Niosomes 
as Nanoparticular Drug Carriers: Fundamentals and Recent Applications. Journal of 
Nanomaterials, 2016. doi:10.1155/2016/7372306.  
5. M. Seleci, D. Ag Seleci (10%), F. Stahl, and T. Scheper, Theranostic liposome-
nanoparticle hybrids for drug delivery and bioimaging, International Journal of 
Molecular Sciences, 2017, 18, 1415. 
6. M. Seleci, D. Ag Seleci (5%), R. Joncyzk, F. Stahl, C. Blume, and T. Scheper. Smart 
multifunctional nanoparticles in nanomedicine, BioNanoMaterials, 2016,17, 33–41. 
7. M. Seleci, D. Ag Seleci (10%), M. Ciftci, D. Odaci Demirkol, F. Stahl, S. Timur, T. 
Scheper, and Y. Yagci, Nano-structured Amphiphilic Star-Hyperbranched 
Blockcopolymers for Drug Delivery, Langmuir, 2015, 31, 4542–4551. 
Poster presentations 
96 
 
Poster Presentations 
 
1. D. Ag Seleci, M. Seleci, Frank Stahl, and Thomas Scheper, Design of Aptamer 
Based Drug Delivery, November 9-11th 2015, Crossing Biological Barriers - Advances 
in Nanocarrier Design for Targeted Drug Delivery, Dresden/Germany 
2. M .Seleci, D. Ag Seleci, F. Stahl, and T. Scheper, Multifunctional theranostic 
quantum dot-liposome hybrids for drug delivery and imaging, November 9-11th 2015, 
Crossing Bioligical Barriers - Advances in Nanocarrier Design for Targeted Drug 
Delivery, Dresden/Germany  
3. M. Seleci, D. Ag Seleci, M. Ciftci, D. Odaci Demirkol, F. Stahl, S. Timur, T. 
Scheper, and Y. Yagci, Nano-structured Amphiphilic Star-Hyperbranched 
Blockcopolymers for Drug Delivery, March 10-11th 2015, 2nd Conference of Scientific 
Cooperation between Lower Saxony and Israel, Hanover/Germany   
Curriculum Vitae 
97 
 
Curriculum Vitae 
Personal data 
 
Name   Didem Ag Seleci 
Date of Birth  15.01.1987 
Place of Birth Izmir 
Nationality  Turkish 
 
Education 
06.2014–present  Dr. rer. nat in Chemistry 
   Leibniz University of Hanover, Germany 
Thesis title: Design and application of niosomal drug delivery 
systems 
 Supervisor: Prof. Dr. Thomas Scheper 
09.2011–12.2013  Master's Degree in Biochemistry 
  Ege University, Izmir, Turkey 
  Thesis title: Design and characterization of quantum dots for in 
vitro cell imaging and investigation of their interactions with 
various cancer cells 
  Supervisor: Prof. Dr. Suna Timur 
09.2006–06.2011  B.Sc. in Biochemistry   
 Ege University, Izmir, Turkey  
Thesis title: Preparation and characterization of electrochemical 
malate dehydrogenase biosensor 
  Supervisor: Prof. Dr. Suna Timur 
 
Work experience 
06.2014–present   Research Fellow  
  Institute of Technical Chemistry  
  Leibniz University of Hanover, Hanover, Germany 
 
01.2014–06.2014  Research Fellow  
        Department of Medical Biochemistry 
 Trakya University, Edirne, Turkey 
